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Abstract
Background:  Post-infectious  irritable  bowel  syndrome  (PI-IBS)  prevalence,  small  intestinal  bac-
terial overgrowth  (SIBO),  altered  microbiota,  low-grade  inﬂammation,  and  antibiotic  therapyBacterial
overpopulation;
in IBS  are  all  controversial  issues.
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Aims:  To  conduct  an  evidence-based  review  of  these  factors.
Methods:  A  review  of  the  literature  was  carried  out  up  to  July  2012,  with  the  inclusion  of
additional  articles  as  far  as  August  2013,  all  of  which  were  analyzed  through  the  Oxford  Centre
for Evidence-Based  Medicine  (OCEBM)  system.
Results:  1.  There  is  greater  SIBO  probability  in  IBS  when  breath  tests  are  performed,  but  preva-
lence varies  widely  (2-84%).  2.  The  gut  microbiota  in  individuals  with  IBS  is  different  from  that
in healthy  subjects,  but  a  common  characteristic  present  in  all  the  patients  has  not  been  estab-
lished. 3.  The  incidence  and  prevalence  of  PI-IBS  varies  from  9-10%  and  3-17%,  respectively,
and the  latter  decreases  over  time.  Bacterial  etiology  is  the  most  frequent  but  post-viral  and
parasitic cases  have  been  reported.  4.  A  sub-group  of  patients  has  increased  enterochromafﬁn
cells, intraepithelial  lymphocytes,  and  mast  cells  in  the  intestinal  mucosa,  but  no  differences
between PI-IBS  and  non  PI-IBS  have  been  determined.  5.  Methanogenic  microbiota  has  been
associated  with  IBS  with  constipation.  6.  Rifaximin  at  doses  of  400  mg  TID/10  days  or  550  mg
TID/14 days  is  an  effective  treatment  for  the  majority  of  overall  symptoms  and  abdominal
bloating  in  IBS.  Retreatment  effectiveness  appears  to  be  similar  to  that  of  the  ﬁrst  cycle.
Conclusions:  Further  studies  are  required  to  determine  the  nature  of  the  gut  microbiota  in  IBS
and the  differences  in  low-grade  inﬂammation  between  PI-IBS  and  non  PI-IBS.  Rifaximin  has
shown itself  to  be  an  effective  treatment  for  IBS,  regardless  of  prior  factors.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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basada  en  evidencias
Microbiota,  infecciones  gastrointestinales,  inﬂamación  de  bajo  grado  y
antibioticoterapia  en  el  síndrome  de  intestino  irritable.  Una  revisión  basada  en
evidencias
Resumen
Antecedentes:  Existen  controversias  sobre  la  prevalencia  del  síndrome  de  intestino  irritable
(SII)-postinfeccioso  (PI),  sobrepoblación  bacteriana  (SPB),  alteraciones  en  la  microbiota,  inﬂa-
mación de  bajo  grado  y  antibioticoterapia  en  SII.
Objetivos:  Realizar  una  revisión  basada  en  evidencia  de  estos  factores.
Métodos:  Se  realizó  una  revisión  de  la  literatura  hasta  julio  del  2012  y  se  incluyeron  artículos
adicionales  hasta  agosto  del  2013,  los  cuales  fueron  analizados  mediante  el  sistema  del  Centro
para Medicina  Basada  en  Evidencia  de  la  Universidad  de  Oxford  (OCEBM).
Resultados:  1.  Existe  mayor  probabilidad  de  SPB  mediante  pruebas  de  aliento  pero  la  preva-
lencia es  muy  variable  (2-84%).  2.  La  microbiota  intestinal  es  diferente  en  SII  que  en  sujetos
sanos, pero  no  se  ha  establecido  una  característica  común  presente  en  todos  los  pacientes.
3. La  incidencia  y  prevalencia  del  SII-PI  varía  del  9-10%  y  3-17%,  respectivamente;  esta  última
disminuye  con  el  tiempo.  La  etiología  bacteriana  es  la  más  frecuente,  pero  se  han  reportado
casos posvirales  y  parasitarios.  4.  Existe  un  subgrupo  de  pacientes  con  incremento  de  células
enterocromaﬁnes,  linfocitos  intraepiteliales  y  mastocitos  en  la  mucosa  intestinal,  pero  no  se
han determinado  diferencias  entre  SII-PI  y  SII-No  PI.  5.  La  microbiota  metanogénica  se  asocia
con el  SII  con  estren˜imiento.  6.  La  rifaximina  en  dosis  de  400  mg  TID/10  días  o  550  mg  TID/14  días
es efectiva  en  la  mejoría  de  síntomas  globales  y  distensión  abdominal  en  SII.  La  efectividad  del
retratamiento  parece  ser  similar  a  la  del  primer  ciclo.
Conclusiones:  Se  requieren  más  estudios  para  determinar  la  microbiota  intestinal  propia  del  SII  y
las diferencias  en  inﬂamación  de  bajo  grado  entre  SII-PI  y  SII-No  PI.  La  rifaximina  ha  demostrado
efectividad  en  el  tratamiento  del  SII  independientemente  de  los  factores  anteriores.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
os.
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1. IntroductionThe  pathophysiology  of  irritable  bowel  syndrome  (IBS)  is  not
completely  understood,  but  various  mechanisms  such  as  gas-
trointestinal  motility  disturbances,  visceral  hypersensitivity,
altered  bidirectional  brain-gut  communication,  psychosocial
a
(
o
flterations,  and  stress  have  been  proposed.1 More  recently
 group  of  patients  has  been  described  that  develop  IBS
fter  gastrointestinal  infections,  known  as  post-infectious
PI)  IBS.2 Likewise,  the  presence  of  small  intestinal  bacterial
vergrowth  (SIBO)  in  quantitative  and  qualitative  gut  and
ecal  microbiota  disruptions  has  been  reported.3--4 IBS  has
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lso  been  associated  with  the  presence  of  low-grade  inﬂam-
ation  in  the  intestinal  mucosa  resulting  from  an  increase  in
he  number  of  intraepithelial  lymphocytes,  mast  cells,  and
nterochromafﬁn  cells,5 without  minimizing  the  fact  that
mmunity  alterations  have  been  described  at  the  periph-
ral  level;  such  is  the  case  with  low  levels  of  interleukin
IL)-10  and  the  increase  of  some  pro-inﬂammatory  inter-
eukins  such  as  tumor  necrosis  factor  alpha  (TNF-) and
ther  inﬂammation  mediators.6 In  fact,  it  is  thought  that
lterations  in  the  microbiota  or  SIBO  in  the  small  bowel
ould  increase  intestinal  permeability,  activating  submu-
osal  immunologic  mechanisms  that  in  turn  could  lead  to
ow-grade  inﬂammation.7 Furthermore,  the  mediators  of
his  immunologic  activation  could  stimulate  enteric  nervous
ystem  terminals,  and  even  the  autonomic  nervous  system,
riggering  the  visceral  sensitivity  and  motility  alterations
hat  have  been  described  in  IBS.7--8 On  the  other  hand,  the
resence  of  PI-IBS,  changes  in  the  microbiota,  and  the  asso-
iation  with  SIBO  in  IBS  have  brought  about  the  justiﬁcation
f  antibiotic  use  in  IBS  treatment.8--9
Nevertheless,  despite  all  the  above,  evidence  is  some-
imes  controversial.  On  the  one  hand,  only  one  group  of
atients  develops  PI-IBS  and  not  all  the  patients  present  with
IBO.9--10 The  latter  is  even  more  limited  due  to  the  fact  that
he  breath  tests  for  diagnosing  SIBO  have  not  been  standard-
zed  and  vary  among  studies.11 Moreover,  the  disturbances
n  the  microbiota  are  diverse  and  there  is  a  wide  variety  of
echniques  for  studying  them,  including  the  most  sophisti-
ated  genomic  tests.12 Similarly,  the  presence  of  low-grade
nﬂammation  is  not  universal  and  the  alterations  described
iffer  among  studies,  in  fact,  it  is  uncertain  whether  these
hanges  that  present  in  some  IBS  patients  are  related  only
o  PI-IBS.13 Finally,  the  studies  on  antibiotics  in  IBS  have
valuated  different  doses,  for  different  periods  of  time,  and
ifferent  outcome  variables.14--15
Consequently,  our  aim  was  to  carry  out  an  evidence-
ased  review  on  the  following  aspects  of  IBS:  1.  The
requency  of  SIBO  in  IBS.  2.  The  incidence  and  prevalence  of
I-IBS  and  its  risk  factors.  3.  To  determine  the  alterations  in
he  intestinal  and/or  fecal  microbiota  in  IBS.  4.  To  determine
he  presence  of  bowel  inﬂammation  in  IBS,  analyzing  the
ifferences  between  PI-IBS  and  non  PI-IBS.  5.  To  understand
he  altered  intestinal  function  (motility,  secretion,  visceral
ensitivity)  in  IBS,  in  relation  to  PI-IBS,  SIBO,  and  micro-
iota  disturbances.  6.  To  evaluate  antimicrobial  treatment
n  IBS.
. Methods
.1.  Coordinator  and  reviewers
his  initiative  was  carried  out  by  a  group  of  Mexican  gas-
roenterologists  interested  in  the  subject.  The  coordinator
f  the  group  is  an  IBS  expert  (MS)  and  the  participants  were
hosen  based  on  their  experience  in  gastroenterology  and
heir  training  and  participation  in  clinical  and  basic  research
elated  to  the  theme.  An  expert  in  the  classiﬁcation  of  lev-
ls  of  evidence  and  grades  of  recommendation  (MP)  with
xperience  and  training  in  gastroenterology,  as  well  as  clini-
al  and  statistical  research,  but  who  is  not  an  IBS  expert,
as  also  included  in  the  group.  This  was  purposely  done
s
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o  that  there  would  be  both  a different  perspective  and  a
ore  objective  evidence  evaluation.  The  9 reviewers  were
ivided  into  6  reviewer  groups  (MB,  RC-AH,  ALC-JLT,  YLV-
AV,  MRT  and  MS),  each  receiving  one  of  the  6  issues  to  be
eviewed.
The  project  coordinator  did  a  preliminary  literature
eview  in  PubMed,  using  the  MEDLINE  database  and
ncluding  articles  written  up  to  July  2012.  The  follow-
ng  search  terms  were  employed:  «IBS» AND  «SIBO»,
abnormal  breath  test», «incidence  of  post  infectious
BS»,  «prevalence  of  post  infectious  IBS»,  «microbiota»,
Post  infectious  IBS» AND  «risk  factors», «epidemiology»,
low  grade  inﬂammation», «Microbiota», «dysbacteriosis»,
SIBO», «methane» AND  intestinal  function»,  «intestinal
otility»,  «sensory  function»,  «sensory  abnormalities»,
visceral  hypersensitivity».
Once  identiﬁed,  the  articles  were  distributed  to  those
esponsible  for  each  theme  to  be  reviewed.  Systematic
eviews  with  or  without  meta-analyses  and  original  articles
ere  selected.  Narrative  reviews  were  not  included.  In  addi-
ion,  the  reviewers  were  authorized  to  include  articles  that
ere  not  selected  in  the  initial  review,  but  that  were  iden-
iﬁed  from  other  sources,  such  as  from  the  references  of
n  article  originally  chosen,  or  articles  published  after  July
012  and  up  to  August  31,  2013,  when  the  preparation  of
he  manuscript  concluded.  All  participants  received  a  set
f  instructions  by  email  with  respect  to  the  information  to
e  obtained  from  the  publications,  as  well  as  the  method-
logy  for  classifying  the  levels  of  evidence  and  grades  of
ecommendation.
.2.  Evidence  grading
he  reviewers  analyzed  the  evidence  and  elaborated  state-
ents  based  on  the  available  information.  The  levels  of
vidence  and  grades  of  recommendation  were  evaluated  and
raded  using  the  Oxford  Centre  for  Evidence-Based  Medicine
OCEBM)  system.16 This  system  utilizes  numbers  and  let-
ers  to  evaluate  the  quality  and  the  level  of  evidence  of
linical  studies.  Quality  and  methodology  are  established
ith  the  numbers  1  through  5  and  the  lower  case  let-
er  «a»,  «b»,  or  «c».  The  numbers  indicate  the  quality
f  the  studies  and  the  letters  indicate  the  methodology
mployed.  For  example,  a 1a  study  is  usually  a  system-
tic  review  that  only  includes  high  quality,  homogeneous,
ontrolled  clinical  trials  (the  number  1  indicates  that  only
igh  quality  homogeneous  controlled  clinical  trials  were
ncluded  and  the  letter  «a» indicates  that  it  is  a  system-
tic  review);  a  2  a  study  is  a  systematic  review  (letter
a»)  that  includes  cohort  studies  of  different  quality  that
re  methodologically  considered  to  be  of  lower  quality
nd  level  (number  2)  than  the  controlled  clinical  trials.
 ﬁnal  example:  2  b  is  a  single  individual  cohort  or  a
ingle  controlled  clinical  trial  (letter  «b»)  of  low  quality
number  2).
The  grade  of  recommendation  is  given  in  the  upper  case
etters  A  through  D.  The  letter  A  is  for  statements,  conclu-
ions,  or  recommendations  based  on  information  obtained
rom  high  quality  or  level  1  evidence,  whereas  letter  D  is
iven  to  recommendations  based  on  studies  of  low  scientiﬁc
uality  or  level  5  evidence.16
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2.3.  Evidence  analysis
The  ﬁrst  face-to-face  meeting  of  the  group  was  held  in
August  2012  and  lasted  9  hours.  First  the  OCEBM  system  was
discussed  and  then  the  reviewers  presented  a  summary  of
each  selected  article  in  tables,  including  authors,  journal,
year,  country,  type  of  article  (systematic  review  or  original)
and  design,  diagnostic  criteria  for  IBS,  and  other  selection
criteria  for  the  subjects,  study  methods  and/or  evaluated
treatment,  outcome  variables,  and  results  or  conclusions.
In  addition,  the  reviewers  responsible  for  each  theme  pro-
posed  a  level  of  evidence  for  each  of  the  studies  and  then
presented  the  statements  or  declarations  and  their  grades
of  recommendation.  Each  of  the  assigned  levels  of  evidence
was  discussed  and  were  modiﬁed  and  accepted  by  consen-
sus;  the  same  was  done  for  the  grades  of  recommendation.
Finally,  the  coordinator  presented  a  summary  of  each  one
and  its  pending  work.  In  January  2013  the  second  meeting
was  held,  lasting  8  hours,  and  only  the  6  updated  reviews
were  presented.  Then  in  March  2013  each  reviewer  sent  his
or  her  written  participation  to  the  coordinator  who  then  sent
each  of  the  sections  to  be  cross-reviewed.  In  other  words,
each  reviewer  or  reviewer  group  went  over  another  group’s
section.  Once  this  cross-review  was  completed,  the  coordi-
nator  proceeded  to  edit  the  manuscript,  after  which  it  was
reviewed  again  by  all  the  participants.
3. Results
In  the  preliminary  PubMed  review,  183  references  were  iden-
tiﬁed;  60  were  eliminated  because  they  were  duplicated,
leaving  123  selected  articles.  Later,  9  additional  articles
from  other  sources  were  added.  The  articles  identiﬁed  in
the  initial  search  and  those  selected  from  other  sources  are
described  in  each  section.  The  results  of  the  6  aspects  cov-
ered  in  the  review  are  described  below.  Each  section  begins
with  the  statements  and  their  respective  levels  of  evidence
and  grades  of  recommendation,  followed  by  the  correspond-
ing  summary.
3.1.  1.  Frequency  of  small  intestinal  bacterial
overgrowth  (SIBO)  in  irritable  bowel  syndrome
•  Different  studies  have  suggested  that  patients  with  IBS
have  a  greater  probability  of  having  SIBO,  determined
through  hydrogen  breath  tests  (level  3  evidence,  grade  B
recommendation).
•  The  reported  prevalence  of  SIBO  in  patients  with  IBS
varies  widely  due  to  the  different  criteria  for  deﬁning
a  positive  breath  test  and  the  methodology  employed
(28  to  84%  with  the  lactulose  breath  test  [LBT],  2  to  31%
with  the  glucose  breath  test  [GBT],  and  2  to  6%  based  on
cultures)  (level  3-4  evidence,  grade  C  recommendation).
Twenty-four  articles  were  identiﬁed  that  reported  on  the
prevalence  of  SIBO  in  IBS; 3,11,17--38 23  articles  during  the
initial  search,3,11,17--35,37--38 and  an  additional  article  identi-
ﬁed  through  manual  search  during  the  preparation  of  the
document.36 Two  systematic  reviews  with  a  meta-analysis
that  included  more  than  3,400  subjects  and  compared
patients  with  IBS  and  healthy  controls  showed  that  the
v
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reath  tests  for  SIBO  were  abnormal  in  the  patients,  with
 4-times  higher  probability  than  the  controls.3,17 An  exten-
ive  bibliographic  search  was  carried  out  in  both  reviews,  the
tudies  were  adequately  selected,  and  the  authors  made  a
lear  reference  to  the  heterogeneity  of  the  studies  (Table  1).
On  the  other  hand,  a  case  series  of  patients  with  IBS
hat  participated  in  an  open  study  with  rifaximin,  showed
 SIBO  prevalence  of  71%  with  LBT  in  IBS.37 In  addition,
6  case-control  studies11,18--30,36,38 provided  information  on
IBO  prevalence  in  IBS,  including  the  study  by  Pimentel
t  al.;18 the  prevalence  of  this  comparative  controlled  clin-
cal  trial  with  placebo  was  the  result  of  a  sub-analysis  of
he  study  population.  A  second  study  analyzed  a  series
f  consecutive  patients  with  diverse  digestive  disorders
hat  were  referred  for  upper  endoscopy;  they  had  duo-
enal  aspiration  culture  done  to  determine  SIBO  and  IBS
as  considered  a  posteriori.36 In  this  same  study  SIBO  was
lso  compared  in  those  patients  with  IBS-D  and  IBS-Non  D,
hich  made  it  incomparable  with  all  the  other  studies.36
f  the  14  remaining  studies,  5  demonstrated  greater  SIBO
revalence  in  IBS  compared  with  the  controls;3,17,19,24,38 7
howed  equal  prevalence,11,20--22,26--27,30 one  showed  lower
revalence  in  IBS,28 and  one  did  not  report  the  p  value,
lthough  there  appeared  to  have  been  a  greater  preva-
ence  in  IBS23 (Table  1).  Among  the  analyses  with  greater
revalence  in  IBS,  the  study  by  Pimentel  et  al.  stands  out
ecause  it  analyzed  the  prevalence  of  SIBO  among  patients
ith  ﬁbromyalgia,  IBS,  and  healthy  controls.19 The  patients
ith  ﬁbromyalgia  were  selected  regardless  of  their  digestive
ymptoms  and  were  the  group  with  the  highest  SIBO  preva-
ence,  above  that  of  the  IBS  patients  and  the  healthy  controls
100,  84,  and  20%,  respectively).  It  should  be  stressed  that
nly  one  Latin  American  study  was  identiﬁed.21 In this  study,
adrid  et  al.,  in  Chile,  found  that  the  prevalence  of  SIBO  was
imilar  in  patients  with  IBS,  compared  with  that  of  other
unctional  gastrointestinal  disorders  (IBS:  76%;  functional
onstipation:  73%;  functional  diarrhea:  69%;  and  functional
loating:  68%).21 Another  study  analyzed  patients  treated
ith  proton  pump  inhibitors  (PPIs)  vs  those  that  were  not,
nding  no  apparent  differences  in  SIBO  frequency.25 And
nally,  two  other  studies  compared  IBS  vs  other  functional
astrointestinal  disorders  (FGIDs).26,29 Six  case  series  with
 combined  total  of  478  patients  were  analyzed  as  well,
nd  a  prevalence  of  SIBO  was  reported  in  patients  with
BS  that  varied  from  36  to  74%,  depending  on  the  methods
mployed.31--35,37
The  use  of  breath  tests  for  diagnosing  SIBO  has  been
haracterized  by  the  lack  of  a  standardized  methodology
nd  validated  criteria  for  deﬁning  an  abnormal  test.  In  the
ajority  of  the  studies  lactulose  was  the  substrate,  but  with
 wide  variety  of  doses,  protocols  for  carrying  out  the  tests,
nd  criteria  for  determining  that  a  test  is  abnormal.  Wal-
ers  et  al.  used  the  LBT  and  applied  2  different  criteria
n  their  interpretation.20 They  included  39  patients  with
BS  and  20  healthy  controls,  ﬁnding  a  radically  different
IBO  prevalence  in  patients  with  IBS,  even  though  there  was
o  difference  in  the  comparison  with  the  healthy  controls,
egardless  of  the  criterion  used:  28%  of  the  patients  with  IBS
s  30%  of  the  control  subjects  when  the  criterion  of  more
han  20  ppm  of  H2 in  the  ﬁrst  90  min  of  the  test  was  used,
ompared  with  69%  of  the  patients  with  IBS  vs  75%  of  the
ontrols  when  the  criterion  of  more  than  20  ppm  of  H2 at
100
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Table  1  Prevalence  of  SIBO  in  IBS.
Author,  journal,
year
Country  Type  of  study  Diagnostic  criteria/Study
groups
n  Test
employed
Outcome  variables  Results/Conclusions  LE
Ford  et  al.,
Clin
Gastroenterol
Hepatol,
20093
Canada  USA  Systematic  review
of  case-control
studies
Manning,
Kruis,
Rome
IBS
vs
healthy  subjects
1,921
vs
326
LBT,
GBT,
XBT,
Culture
Prevalence  of  SIBO
and  positive  tests
IBS,  LBT:  54%;  GBT:  31%;  XBT  (a
single  study):  33%,  culture:  4%
(a single  study).
The  accumulated  probability  of
one  test  for  +SIBO  in  IBS  vs
controls  is:  OR  3.4  (95%  CI
0.9-12.7)  to  OR  4.7  (95%  CI
1.7--12.9),  depending  on  the
criteria  used
3a
Shah et  al.,
Dig  Dis  Sci,
201017
USA  Systematic  Review
+
meta-analysis  of
case-control
studies
Rome  I,  II,  III
IBS
vs
healthy  subjects
1,076
vs
509
LBT,
GBT,
FBT,
XBT
Probability  of
abnormal  tests
IBS  vs  controls:  OR  4.46  (95%  CI
1.7 11.8)
3a
Pimentel et  al.,
Am  J
Gastroente-rol,
200318
USA  Case-control  Rome  I
IBS
vs
healthy  subjects
111
vs
15
LBT  SIBO  prevalence  IBS:  84%  vs  controls:  20%;
(p  <  0.01)
3b
Pimentel et  al.,
Ann  Rheum  Dis,
200419
USA  Case-  control  Rome  I
IBS
vs
FM  ACR
1990
111
vs
42
LBT  SIBO  prevalence  IBS:  84%  vs  controls:  20%,
(p  <  0.01),  vs  FM:  100%;
(p  <  0.05)
3b
Walters et  al.,
Am  J
Gastroenterol,
200520
Canada  Case-  control  Rome  II
IBS
vs
healthy  subjects
39
vs
20
LBT,  XBT  SIBO  prevalence  H2  >  20  ppm  between  90  and
180  min,  IBS:  28%  vs  controls:
30%,  (p  =  NS)
H2  >  20  ppm  in  the  ﬁrst  90  min,
IBS: 69%  vs  controls:  75%,
(p  =  NS)
3b
Madrid et  al.,
Rev  Med  Chile,
200721
Chile  Case-  control  Rome  II
IBS
vs
controls  (functional
bloating  vs
functional  constipation
vs
functional  diarrhea)
225
vs
83
vs
33
vs
26
LBT  SIBO  prevalence  IBS:  76%  vs  controls:  76%;
(p  =  NS);
IBS-C:  73%,  IBS-D:  76%,  IBS-A:
79.7%
3b
Posserud et  al.,
Gut,
200722
Sweden  Case-  control  Rome  II
IBS
vs
healthy  subjects
162
vs
42
Culture  SIBO  prevalence  IBS:  4%  vs  controls:  4%;  (p  =  NS).
Of  the  patients  with  SIBO,
IBS-C:  43%,  IBS-D:  28.5%,  IBS-A:
28.5%
3b
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Table  1  (Continued)
Author,  journal,
year
Country  Type  of  study Diagnostic  criteria/Study
groups
n  Test
employed
Outcome  variables Results/Conclusions LE
Bratten  et  al.,
Am  J
Gastroenterol,
200811
USA  Case-  control  Rome  II
IBS
vs
healthy  subjects
224
vs
30
LBT  SIBO  prevalence  IBS:  20%  vs  controls:  15%;
(p  =  0.79)
3b
Grover et  al.,
J  Neurogastro
Motil,
200823
USA,  Japan Case-  control Rome  II
IBS
vs
healthy  subjects
158
vs
34
XBT  SIBO  prevalence IBS:  32.9  vs  controls:  17.9%
(p  =  not  reported);
SIBO  according  to  IBS  subtype,
IBS-C:  30.8%,  IBS-D:  30.8%,
IBS-M:  38.5%
3b
Scarpellini et  al.,
J  Pediatr,
200938
Italy  Case-  control Children  with  IBS
Rome  II
vs
healthy  subjects
43
vs
56
LBT  SIBO  prevalence IBS:  65%  vs  controls:  7%;  (OR
3.9, 95%  CI:  7.3-80.1,  p  <  0.001)
3b
Parodi et  al.,
J  Clin
Gastroenterol,
200924
Italy  Case-  control Rome  III
IBS
vs
Rome  III
functional  bloating
vs
healthy  subjects
130
vs
70
vs
70
GBT  SIBO  prevalence IBS:  16.5%  vs  functional
bloating:  2.8%  vs  controls:
4.2%;  (p  =  0.0137);
SIBO  according  to  IBS  subtype,
IBS-D:  52.3%,  IBS-C  and  IBS-M:
the exact  frequency  is  not
reported
3b
Law et  al.,
Dig  Dis  Sci,
201025
USA  Case-  control  Rome  I  IBS
with  PPI
vs
without  PPI
106
vs
449
LBT  SIBO  prevalence  IBS:  54.4%;
IBS  +  PPI:  46.2%  vs  IBS  -  PPI:
56.3%,  (OR  0.67,  95%  CI
0.436-1.017,  p  =  0.06)
3b
Park et  al.,
Korean  J
Gastroeterol,
201026
South  Korea Case-  control Rome  II
IBS
vs
Rome  II
other  FGID
vs
healthy  subjects
76
vs
70
vs
40
LBT  SIBO  prevalence IBS:  45%  vs  FGID:  41%  vs
controls:  40%,  (p  =  0.97);
IBS-C:  11.8%,  IBS-D:  58.8%,
IBS-M:  29.4%
3b
Ghoshal et  al.,
Neurogastro-
enterol  Motil,
201027
India  Case-  control Manning  IBS
vs
NSCD
vs
healthy  subjects
129
vs
73
vs
51
GBT  SIBO  prevalence  IBS:  8.5%  vs  NSCD:  21.9%  vs
controls:  2%;  (IBS  vs  NSCD,
p  =  0.007;  IBS  vs  controls,
p =  0.18;  NSCD  vs  controls,
p =  0.003)
3b
Choung et  al.,
Aliment
Pharmacol  Ther,
201128
USA,
Australia
Case-  control IBS
vs
endoscopy  patients
148
vs
527
Duodenal  aspirate
culture
SIBO  prevalence  in
IBS
IBS:  2%  vs  controls:  10%,
(p =  non-speciﬁc)
3b
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Table  1  (Continued)
Author,  journal,
year
Country  Type  of  study  Diagnostic  criteria/Study
groups
n  Test
employed
Outcome  variables  Results/Conclusions  LE
Yakoob  et  al.,
Saudi  J
Gastroente-rol,
201129
Pakistan  Case-  control  Rome  III
IBS-D
vs
NSCD
119
vs
115
LacBT  SIBO
prevalence
IBS-D:  19%  vs  NSCD:  9%;
(p  =  0.03).
Only  patients  with  IBS-D  were
included
3b
Rana et  al.,
Digestion,
201230
India  Case-  control  Rome  II
IBS-D
vs
healthy  subjects
175
vs
150
LBT
GBT
SIBO  prevalence  LBT,  IBS:  34  vs  controls:  30%,
(p  =  NS)
GBT,  IBS:  6.2  vs  controls:  0.7%,
(p  <  0.01)
3b
Pyleris et  al.,
Dig  Dis  Sci,
201236
Greece  Case-  control  Rome  II
IBS,  IBS-D,  IBS-Non  D
that  underwent
endoscopy
42  Culture  from  the
third  portion  of
the  duodenum
SIBO  prevalence
in  IBS  and  IBS-D
vs
IBS-Non  D
IBS:  37.5%  and  IBS-D:  60%  vs
IBS-Non  D:  27.3%,  (p  =  0.004)
3b
Pimentel et  al.,
Am  J
Gastroenterol,
200331
USA  Case  series  Rome  II
IBS-D
20  LacBT,
LBT,  concordance
between  the  2
SIBO  prevalence  LacBT:  53%;
LBT:  74%;
correlation:    =  0.29,
+H  >  166  ppm  in  LacBT,  it  was  a
predictor  of  +LBT
4
Esposito et  al.,
World  J  Gastro,
200732
Italy  Case  series  Rome  II
IBS
73  LBT  SIBO  prevalence  SIBO  prevalence,
IBS:  45%
4
Peralta et  al.,
World  J
Gastroente-rol,
200933
Italy  Case  series  Rome  II
IBS
97  LBT  SIBO  prevalence  SIBO,
IBS:  55.6%,
IBS-C:  52.2%,  IBS-D:  61.3%,
IBS-M:  52%
4
Reddymasu et  al.,
BMC
Gastroente-rol,
201034
USA  Case  series  Rome  II
IBS
98  GBT  SIBO
prevalence
SIBO,
IBS:36%  (IBS-C:  54%,  IBS-D:
43%,  IBS-M:  3%)
4
Yu et  al.,
Gut,
201135
Canada  Case  series  Rome  II
IBS
40  LBT  SIBO
prevalence
SIBO,
IBS:  63%
4
Meyrat et  al.,
Aliment
Pharmacol  Ther,
201237
Switzerland  Case  series  Rome  III
IBS
150  LBT  SIBO  prevalence  SIBO,
IBS:  71%
4
The studies are organized from higher to lower level of evidence and then in the progressive order of publication year. The prevalence of SIBO is only given according to the IBS subtypes
in the studies that reported them.
ACR: American College of Rheumatology; FBT: fructose breath test; FGID: functional gastrointestinal disorders; FM: ﬁbromyalgia; GBT: glucose breath test; H2: exhaled hydrogen; IBS:
irritable bowel syndrome; IBS-A: alternating irritable bowel syndrome; IBS-C: irritable bowel syndrome with constipation; IBS-D: irritable bowel syndrome with diarrhea; IBS-M: mixed
irritable bowel syndrome; LacBT: lactose breath test; LBT: lactulose breath test; LE: level of evidence; 95% CI: 95% conﬁdence interval; NSCD: non-speciﬁc chronic diarrhea; NS: not
signiﬁcant; N: number; OR: odds ratio; ppm: parts per million; PPI: proton pump inhibitors; SIBO: small intestinal bacterial overgrowth; XBT: xylose breath test.
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any  time  during  the  ﬁrst  180  min  of  the  test  was  employed.20
Furthermore,  the  accuracy  of  the  LBT  has  been  questioned
because  the  decomposition  of  this  substrate  by  the  bacteria
of  the  cecum  usually  produces  a  second  spike  in  hydrogen
detection  that  reduces  its  speciﬁcity.  In  contrast,  the  GBT,
in  which  the  substrate  is  completely  absorbed  in  the  proxi-
mal  small  bowel  (duodenum),  has  shown  a  greater  sensitivity
and  speciﬁcity  for  the  detection  of  SIBO  than  the  LBT.11 Rana
et  al.  found  a  similar  SIBO  prevalence  in  IBS  patients  and
healthy  subjects  utilizing  the  LBT  (34  vs  30%,  p  =  NS),  but
a  higher  prevalence  of  SIBO  in  IBS  utilizing  the  GBT  (6.2  vs
0.66%,  p <  0.01).30 Despite  its  apparently  being  a  more  pre-
cise  test,  it  has  been  employed  in  fewer  studies.24,27,32,36
Sucrose,  another  substrate  that  is  totally  absorbed  in  the
small  bowel  and  therefore  theoretically  more  accurate,  was
used  in  only  one  of  the  selected  studies.23
On  the  other  hand,  the  presence  of  SIBO  has  also  been
deﬁned  based  on  the  detection  of  an  elevated  bacterial
count  from  small  bowel  ﬂuid  culture.  The  quantitative
culture  should  then  be  regarded  as  the  benchmark  test  for
SIBO,  but  it  has  been  utilized  in  very  few  studies.  How-
ever,  it  would  depend  on  the  culture  site  and  many  bacteria
are  unculturable.  Only  2  of  the  selected  studies  employed
culture  for  detecting  SIBO,22,28 and  as  mentioned  before,
one  of  them  reported  a  lower  SIBO  frequency  in  IBS  vs
control  subjects  with  different  pathologies  that  underwent
endoscopy.28
We  can  therefore  conclude  that  there  is  evidence  sug-
gesting  a  greater  probability  of  SIBO  in  IBS  according  to
breath  test  data,  but  there  is  not  enough  evidence  for
recommending  the  routine  use  of  these  tests  for  diagnosing
SIBO  in  IBS.
3.2.  2.  Alterations  in  the  gut  microbiota
(dysbiosis)  in  irritable  bowel  syndrome
•  The  composition  of  the  microbiota  in  patients  with  IBS
is  different  from  that  of  normal  subjects  (level  3  b  evi-
dence,  grade  B  recommendation).
•  Alterations  in  the  composition  of  the  microbiota  -
dysbiosis-  occur  in  both  adult  and  pediatric  patients  with
IBS  (level  3  b  evidence,  grade  B  recommendation).
•  Due  to  the  heterogeneity  of  IBS  and  the  use  of  different
methods  for  studying  the  gut  microbiota,  it  is  not  possible
to  establish  a  microbial  composition  characteristic  of  IBS
(level  3  b  evidence,  grade  B  recommendation).
Twenty-six  published  articles  were  identiﬁed  that  stud-
ied  the  composition  of  the  microbiota  in  patients  with  IBS;
24  in  the  initial  search41--64 and  2  from  other  sources.39,40
All  of  them  are  case-control  studies  conducted  in  Europe,
Asia,  and  the  United  States;  none  from  Latin  Amer-
ica  or  Africa.  Twenty-ﬁve  were  carried  out  on  adult
population39--55,57--64 and  only  one  on  children.56 In  11  of
the  studies,  the  cases  were  classiﬁed  according  to  the  IBS
subtype.41,43,46--48,52,55--56,60,62,64 The  microbiota  was  analyzed
with  molecular  methods  in  the  majority  of  the  studies,
whereas  just  fecal  culture  was  used  in  2,39,40 and  both
methodologies  were  used  in  4  studies.42,48,51,58 Even  though
the  majority  of  the  studies  analyzed  the  composition  of
the  microbiota  in  samples  of  fecal  matter,  the  microbial
t
t
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omposition  was  also  examined  in  biopsies  of  the  colonic
ucosa  in  4  of  the  studies.  The  predominant  results  of  each
f  these  studies  and  the  summary  of  the  microbial  ecology
f  the  gut  microbiota  in  IBS  are  shown  in  Table  2.
The  investigations  that  used  fecal  cultures  for  studying
he  gut  microbiota  have  shown  that  IBS  patients,  unlike
ealthy  subjects,  have  a  diminished  population  of  biﬁ-
obacteria  and  lactobacilli  and  an  increased  population  of
treptococci,  coliforms,  and  Clostridium  species.39,40,42,51
oreover,  the  majority  of  the  studies  used  molecular  meth-
ds  independent  of  the  culture,  such  as  tests  based  on  DNA
xtraction  and  ampliﬁcation  of  the  16S  genes  of  riboso-
al  RNA,  quantitative  PCR,  the  products  of  PCR  through
enaturing  gradient  gel  electrophoresis,  and  probe-speciﬁc
uorescence  in  situ  hybridization.  The  many  different
olecular  strategies  employed  in  these  studies  (Table  3)
s  the  reason  for  the  inconsistent  and  even  contradictory
esults  in  relation  to  the  composition  and  diversity  of  the
icrobiota  in  patients  with  IBS,  as  well  as  a  single  deter-
ination  of  the  microbiota  in  the  variable  of  time  and  the
imited  knowledge  of  new  bacterial  species  that  are  still
aiting  to  be  described.  Thus,  even  though  it  seems  that  the
ut  microbiota  of  patients  with  IBS  is  different  from  that  of
he  controls,  it  is  not  yet  possible  to  establish  an  intestinal
icrobial  composition  characteristic  of  IBS.
.3.  3. Incidence  and  prevalence  of
ost-infectious  irritable  bowel  syndrome  (PI-IBS)
 The  average  incidence  of  PI-IBS  has  been  reported  as  9  to
10%  with  a  4  to  36%  interval  (level  1  a  evidence,  grade  A
recommendation).
 The  prevalence  of  PI-IBS  varies  from  3  to  17%  and
decreases  over  time  after  gastrointestinal  infection
(level  3  b  evidence,  grade  B  recommendation).
 The  most  studied  etiology  in  relation  to  PI-IBS  is  that  of
bacterial  origin,  and  even  though  the  viral  and  parasitic
causes  have  scarcely  been  studied,  they  also  appear  to
be  risk  factors  for  PI-IBS  (level  2  b  evidence,  grade  B
recommendation).
Twenty-three  studies  on  PI-IBS  were  reviewed,  19  of
hich  were  identiﬁed  in  the  initial  search10,65--82 and  4
fterwards  from  other  sources.83--86 Twelve  studies  reported
he  incidence  of  PI-IBS  (new  onset  IBS),65--67,71--72,75,77,80,83,85
 reported  the  prevalence,65,69,73,74,78,79,82,84 and  8  ana-
yzed  the  risk  factors  related  to  the  development  of
I-IBS.10,66,70,72,82,84,86 All  the  studies  were  conducted  on
dult  population,  with  the  exception  of  one  on  pediatric
opulation71 (Table  4).
The  incidence  of  clinical  symptoms  of  IBS  after  a  gas-
rointestinal  infection  has  been  reported  at  an  average  of
-10%  based  on  2  systematic  reviews,  but  varies  depend-
ng  on  the  case  from  4  to  36%.65,67 There  are  no  differences
f  IBS  develops  after  an  acute  gastroenteritis  episode  dur-
ng  epidemics,  due  to  isolated  infections,  or  after  traveler’s
iarrhea.65 Likewise,  the  probability  of  developing  IBS  is  6
imes  higher  in  subjects  that  have  been  exposed  to  gastroin-
estinal  infections  than  in  those  that  have  not.66
The  prevalence  of  PI-IBS  has  been  reported  in  7  to
3%  of  patients,  but  there  are  wide  variations  depend-
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Table  2  Studies  on  the  composition  of  the  intestinal  microbiota  in  patients  with  IBS.
Author,
journal,
year
Country  Type  of  study  Diagnostic
criteria/Study
groups
n  Sample  Method  Results/Conclusions  LE
Balsari  et  al.,
Microbiologica,
198239
Italy  Case-control  Nonspeciﬁed  IBS
criteria
vs
healthy  controls
20
vs
20
Stool  Culture  Composition  of  the  microbiota,
IBS  vs  controls:  <  Lactobacillus
spp,  <  Biﬁdobacterium  spp,
< Coliforms
3b
Si et  al.,
World  J
Gastroenterol,
200440
China  Case-control  Rome  II
IBS
vs
healthy  controls
25
vs
20
Stool  Culture  Number  of  bacteria,
IBS  vs  controls:  <  Enterobacteriaceae,
>  Biﬁdobacterium,  (both  p  <  0.05)
3b
Malinen et  al.,
Am  J
Gastroenterol,
200541
Finland  Case-control  Rome  II
IBS
vs
healthy  controls
27
vs
22
Stool  qPCR  Total  bacteria,
IBS  vs  controls:  <  C.  coccoides,  (p  <  0.04)
IBS-D:  <Lactobacillus  spp,  (p  <  0.019)
IBS-C:  >Veillonella  spp,  (p  <  0.045)
3b
Matto et  al.,
Immunol  Med
Microbiol,  200542
Finland  Case-control  Rome  II
IBS
vs
healthy  controls
26
vs
25
Stool  Culture,
PCR-DGGE
Composition  of  the  microbiota,
IBS  vs  controls:  >  Coliforms,  >
Aerobic/Anaerobic
Temporal  stability,
IBS  <  controls
3b
Maukonen et  al.,
J Med  Microbiol,
200643
Finland  Case-control  IBS-D  vs  IBS-C  vs
IBS-M
nonspeciﬁed
criteria
vs
healthy  controls
7  vs  6  vs
3  vs
16
Stool  PCR-DGGE  Predominant  microbiota,
in  all:  C.  coccoides-Eubacterium  rectale,
IBS-C:  30%  vs  IBS-D:  50%  vs  controls:  43%;
temporal  stability,
IBS  <  controls
3b
Kassinen et  al.,
Gastroenterolo-
gy,
200744
Finland  Case-control  Rome  II
IBSD  vs  IBS-C  vs
IBS-M
vs
healthy  controls
10  vs  8
vs  6  vs
23
Stool  16S  rRNA
sequencing,
qPCR
Composition  of  the  microbiota,
IBS:  <  Lactobacillus  (almost  nonexistent)
and  Collinsella  (especially  in  IBS-D  and
IBS-M)  vs  controls;
IBS-D:  abundant  Streptococcus  and  <
Biﬁdobacteria,
IBS-C:  abundant  Ruminococcus,
IBS-M:  Predominance  of  Bacteroides  and
Allisonella
3b
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Table  2  (Continued)
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n  Sample  Method  Results/Conclusions  LE
Kerckhoffs  et  al.,
World  J
Gastroenterol,
200945
The
Netherlands
Case-control  Rome  II
IBS
vs
healthy  controls
41
vs
26
Stool,
duodenal
mucosa
FISH,
qPCR
Composition  of  the  microbiota,
IBS  vs  controls:  Biﬁdobacteria,
4.2  ±  1.3  vs  8.3  ±  1.9  (p  <  0.01),
Biﬁdobacterium  catenulatum,
6 ±  0.6  vs  19  ±  2.5,  (p  <  0.001)
3b
Krogius-Kurikka
et al.,
BMC
Gastroenterol,
200946
Finland  Case-control  Rome  II
IBS-D
vs
healthy  controls
10
vs
23
Stool  16S  rRNA
sequencing
Composition  of  the  microbiota,
IBS-D  vs  controls:  >  Proteobacteria,
Firmicutes  (family  Lachnospiraceae),
< Actinobacteria,  Bacteroidetes
3b
Lyra et  al.,
World  J
Gastroenterol,
200947
Finland  Case-control  Rome  II
IBS-C
vs
healthy  controls
20
vs
15
Stool  qPCR  Characteristic  phylotypes,
85%≈C.  thermosuccinogenes,
IBS-D:  -4.08  ±  0.90  vs  controls:
-3.33  ±  1.16  (p  =  0.04),  vs  IBS-M:
-3.08  ±  1.38  (p  =  0.05);
94%  ≈R.  torques,  IBS-D:  -2.43  ±  1.49  vs
controls:  -4.02  ±  1.63  (p  =  0.01);
93%≈R.  torques, controls:  -2.41  ±  0.53
vs IBS-M:  -2.92  ±  0.56  (p  =  0.00);
R. bromii-like  in  IBS-C:  -1.61  ±  1.83  vs
controls:  -3.69  ±  2.42  (p  =  0.01)
3b
Carroll et  al.,
Gut  Pathog,
201048
USA  Case-control  Nonspeciﬁed  IBS-D
criteria
vs
healthy  controls
10
vs
10
Stool,
colonic
mucosa
Culture,
qPCR
Composition  of  the  fecal  microbiota,
IBS-D:  1.4  ×  107 vs  controls:  8.4  ×  108
CFU/g  feces  (p  =  0.002)
> 3.6  Lactobacillus  spp  (p  =  0.002);
colonic  mucosa,  with  no  differences
3b
Codling et  al.,
Dig  Dis  Sci,
201049
Ireland  Case-control  Rome  II
IBS
vs
healthy  controls
47
vs
33
Stool,
colonic
mucosa
DGGE  of  the
16S  rRNA  gene
Composition  of  the  fecal  microbiota,  IBS
vs controls:  <  variability  (p  <  0.001);
with  no  differences  between  stool  and
mucosa
3b
Noor et  al.,
BMC
Gastroenterol,
201050
United
Kingdom
Case-control  Rome  II
IBS
vs
UC
vs
healthy  controls
11
vs
13
vs
22
Stool  PCR-DGGE  and
16S  rRNA
sequencing
Number  of  bacterial  bands,
IBS:  39  ±  6  vs  UC:  37  ±  5  vs  controls:
45 ±  3  (p  =  0.01);
<  Bacteroides  and  Parabacteroides
biodiversity,
IBS, UC  <  controls  (p  =  0.01)
3b
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Malinen  et  al.,
World  J
Gastroenterol,
201064
Finland  Case  series  Rome  I
IBS
44  Stool  qPCR  Composition  of  the  microbiota,
94%≈R.  torques-like,  was  associated
with  IBS  symptom  severity;
IBS  with  94%≈R.  torques:  <  C.
cocleatum,  C.  aerofaciens-like  and  C.
eutactus  97%
4
Tana et  al.,
Neurogastroenterol
Motil,
201051
Japan  Case-control  Rome  II
IBS
vs
healthy  controls
26
vs
26
Stool  Culture,
qPCR
Altered  microbiota  (log10 bacteria  g−1),
Veillonella  spp,  IBS:  7.2  ±  0.8  vs
controls:  6.8  ±  0.7  (p  =  0.046),
Lactobacilli  spp,  IBS:  5.6  ±  1.9  vs
controls:  4.6  ±  1.6,  (p  =  0.031)
3b
Carroll et  al.,
Am  J  Physiol
Gastrointest  Liver
Physiol,
201152
USA  Case-control  Rome  III
IBS-D
vs
healthy  controls
16
vs
21
Stool,
colonic
mucosa
PCR  with  16S
rRNA  primers
Biodiversity  in  stool,
IBS-D  vs  controls:  <  1.2  times  (p  =  0.008);
no differences  in  the  colonic  mucosa
3b
Kerckhoffs et  al.,
J  Med  Microbiol,
201163
Holland  Case-control  Rome  II
IBS
vs
controls
37
vs
20
Stool,
duodenum
PCR-DGGE  Composition  of  the  microbiota,
Pseudomonas  48%  of  clones
duodenum,
IBS:  8.3  ±  0.9  vs  controls:  0.1  ±  0.007
(p <  0.001);  stool,  IBS:  2.34  ±  0.31  vs
controls:  0.003  ±  0.0027  (p  <  0.001)
3b
Ponnusamy et  al.,
J  Med
Microbiology,
201153
Korea  Case-control  Rome  II
IBS
vs
healthy  controls
11
vs
8
Stool  qPCR
DGGE
of  16S  rRNA
genes
Bacterial  diversity,
IBS-D  >  controls,  (p  =  0.004),  <
Biﬁdobacter  and  C.  coccoides;
Number  of  bacteria,
IBS  =  controls
3b
Rajilic-Stojanovic
et al.,
Gastroenterolo-
gy,
201154
Holland  Case-control  Rome  II
IBS
vs
healthy  controls
62
vs
46
Stool  16S
phylogenetic
microarrays
and  qPCR
Firmicutes-Bacteroides  ratio,
IBS  vs  controls:  x2  (p  =  0.0002),  x1.5
Dorea,  Ruminococcus  and  Clostridium
spp  (p  =  0.005),  x2  Bacteroidetes
(p  =  0.0001),  x1.5
Biﬁdobacterium  and  Faecalibacterium
spp  (p  =  0.05);
methanogens,
IBS:  3.50  ±  107  vs  controls:  8.74  ±  106
cells/g  feces  (p  =  0.003)
3b
M
icrobiota,
 gastrointestinal
 infections,
 low
-grade
 inﬂ
am
m
ation,
 and
 antibiotic
 therapy
 
107
Table  2  (Continued)
Author,
journal,
year
Country  Type  of  study Diagnostic
criteria/Study
groups
n  Sample  Method  Results/Conclusions  LE
Rinttila  et  al.,
Gut  Pathog,
201155
Finland  Case-control  Rome  I
IBS-D
vs
healthy  controls
96
vs
23
Stool  qPCR  S.  aureus  prevalence,
IBS:  17%  vs  controls:  0  (p  <  0.05),
C. perfringes,
IBS:  13%  vs  controls:  17%  (NS)
3b
Saulnier et  al.,
Gastroenterolo-
gy,
201156
USA  Case-control  Children  with
Rome  III
IBS-C
vs
healthy  controls
22
vs
22
Stool  16S  rRNA
metagenomic
sequencing
and  DNA
microarrays
Composition  of  the  microbiota,
IBS-C  vs  controls:  >  0.07%
Proteobacterias  (Haemophilus
parainﬂuenzae);
a novel  Ruminococcus-like  microbe,  was
associated  with  IBS
3b
Carroll et  al.,
Neurogastroenterol
Motil,
201257
USA  Case-control  Rome  II
IBS-D
vs
healthy  controls
23
vs
23
Stool  High
performance
DNA
sequencing
Composition  of  the  microbiota,
IBS:  >  Enterobacteriacea,
(p  =  0.03),  <  Fecalibacterium  (p  =  0.04)  vs
controls
3b
Chassard et  al.,
Aliment
Pharmacol  Ther,
201258
France  Case-control  Rome  II
IBS-C
vs
healthy  controls
14
vs
12
Stool  Culture  and
FISH
Composition  of  the  microbiota,
Enterobacteria,  IBS-C:  7.4  ±  0.8  vs
controls:  6.4  ±  0.9  (p  =  0.01),
Biﬁdobacteria,  6.8  ±  0.7  vs  7.8  ±  0.5
(p <  0.0001),
lactobacilli,  5.5  ±  0.9  vs  6.9  ±  0.7
(p =  0.0007),
lactate  utilizers,  7.9  ±  1.2  vs  9.3  ±  0.4
(p =  0.0046),
sulfate  utilizers,  8.4  ±  0.3  vs  5.9  ±  0.4
(p =  0.0002),
<  butyrate  producers,  Roseburia-E.
rectale  (Lachnospiraceae)  (p  <  0.05)
3b
Duboc et  al.,
Neurogastroenterol
Motil,
201259
France  Case-control  Rome  III
IBS
vs
healthy  controls
14
vs
18
Stool  qPCR  Number  of  bacteria,
IBS-D  vs  controls:  the  same  number  of
bacteria,  >  E.  coli  (p  =  0.002),
< Leptum  (p  <  0.001),  <  Biﬁdobacteria
(p  =  0.007)
3b
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Jeffery  et  al.,
Gut,
201260
Sweden  Case-control  Rome  II
IBS-D
vs
IBS-C
vs
IBS-A
vs
healthy  controls
15
vs
10
vs
12
vs
20
Stool  16S  rRNA
pyrosequencing
3  IBS  subgroups  were  identiﬁed,
1: microbiota  similar  to  the  controls;
2 and  3:  >  Firmicutes  and  <
Bacteroidetes  vs  controls
3b
Maccaferri et  al.,
Gut  Microbes,
201261
Italy  Case-control  IBS-D
vs
IBS-M
vs
IBS-C
vs
controls
10
vs
5
vs
20
vs
24
Stool  Microarrays  Composition  of  the  microbiota,
IBS  vs  controls:  >  Lactobacilli,  >  B.
cereus, >  B.  clausii,  >  Biﬁdobacteria,  >
Clostridia  IX,  >  E.  rectale,
< Bacteroides/genus  Prevotella  and  <
Veillonella
3b
Parkes et  al.,
Neurogastroenterol
Motil,
201262
United
Kingdom
Case-control  Rome  III
IBS-D
vs
IBS-C
vs
healthy  controls
27
vs
26
vs
26
Colonic
mucosa
FISH,
confocal
micros-copy
Number  of  bacteria/mm3 (IQR),
IBS:  218  (209)  vs  controls:  128  (121),
(p  =  0.007);
Bacteroides,  69  (67)  vs  14  (41),
(p  =  0.001),  E.  rectale--Clostridium
coccoides,  52  (58)  vs  25  (35),  (p  =  0.03),
Biﬁdobacteria,
IBS-D:  24  ±  32  vs  IBS-C:  54  ±  88  vs
controls:  32  ±  35,  (p  =  0.011)
3b
The studies are organized from higher to lower level of evidence and then in the progressive order of publication year.
A: alternating; C: constipation; D: diarrhea; DNA: deoxyribonucleic acid; FISH: ﬂuorescence in situ hybridization; H2: hydrogen; IBS: irritable bowel syndrome; IQR: interquartile range; LE:
level of evidence; N: number; PCR-DGGE: polymerase chain reaction-denaturing gradient gel electrophoresis; qPCR: quantitative polymerase chain reaction; RCT: randomized controlled
trial; rRNA: ribosomal ribonucleic acid; spp: all the species of the genus referred to; UC: nonspeciﬁc chronic ulcerative colitis; >: increase; <:decrease;.
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Table  3  Molecular  methods  used  in  the  microbiota  analysis.
FISH  (Fluorescence  in  situ
hybridization)
FISH  is  a  technique  that  detects  the  sequences  of  nucleic  acids  in  bacteria  and  tissue.  In  situ
detection  provides  direct  visualization  of  the  special  location  of  speciﬁc  sequences,  which  is
crucial for  explaining  the  genetic  organization  and  function.  For  this  reason  the  in  situ
hybridization  method  is  an  important  technique  in  the  diagnosis  of  chromosomal
rearrangement  in  microorganism  detection.  In  situ  hybridization  is  based  on  the
complementariness  of  the  nucleic  acids  of  DNA  and/or  RNA  through  the  hydrogen  bridges
formed between  the  bases:  adenine-thymine  (DNA)  or  uracil  (RNA)  and  cytosine-guanine  (DNA
and RNA)
PCR-DGGE  (ampliﬁcation  by
polymerase  chain
reaction-  denaturing
gradient  gel
electrophoresis)
The  genetic  blueprint  technique  is  useful  for  identifying  bacteria  (isolated  or  in  community)
at the  end  of  a  polymerase  chain  ampliﬁcation  of  its  DNA.  The  genetic  print  consists  of  a
proﬁle based  on  the  physical  separation  of  the  unique  sequence  of  the  16S  ribosomal  RNA
gene through  DGGE.  It  also  enables  the  simultaneous  analysis  of  numerous  bacteria  from  a
clinical sample  or  tissue.  Thus  the  technique  makes  it  possible  to  compare  the  genetic
diversity  of  bacteria  and  the  study  of  their  behavior  at  the  same  time
16S rDNA  (deoxyribonucleic
acid)
16S  rDNA  is  the  gene  that  encodes  for  16s  ribosomal  RNA.  It  is  a  component  of  the  small
subunit of  prokaryotic  ribosomes.  The  16S  rDNA  gene  is  used  for  phylogenetic  studies  because
it is  highly  conserved  among  the  different  bacterial  and  archaeal  species;  in  addition  it
contains hypervariable  regions  that  provide  speciﬁc  species  sequences  that  are  useful  for
bacterial  identiﬁcation.  The  use  of  these  sequences  has  made  it  possible  to  become  aware  of
the existence  of  a  large  number  of  genera  and  species
16S rRNA  (ribonucleic  acid)  16S  rRNA  is  a  polyribonucleotide  of  approximately  1.500  nt,  encoded  by  the  RRS  gene.  It  is  also
designated  16s  ribosomal  DNA  (16S  rDNA)  and  phylogenic  and  taxonomic  information  can  be
obtained from  its  sequencing.  Regarded  as  a  molecular  chronometer  due  to  the  fact  that  it  is
an ancient  molecule  present  in  all  bacteria,  16S  ribosomal  RNA  (rRNA)  is  the  most  widely  used
macromolecule  in  studies  of  bacterial  phylogeny  and  taxonomy.  The  changes  in  its  sequence
data occur  slowly  and  its  variability  enables  it  to  distinguish  organisms  both  nearby  and  distant
Quantitative PCR
(deoxyribonucleic  acid)
Quantitative  polymerase  chain  reaction  (qPCR)  or  real-time  PCR  is  a  variation  of  the  standard
PCR technique  that  is  employed  to  determine  the  number  of  DNA  or  mRNA  copies  present  in  a
sample (measurement  of  gene  expression).  The  microorganisms  in  a  sample  can  be  identiﬁed
and quantiﬁed  by  this  technique,  which  is  very  useful  for  the  diagnosis  and  treatment  of
patients
Phylogenetic microarray  Microarrays  are  made  up  of  biologic  or  synthetic  material  and  a  solid  support  in  which  it  is
immobilized  or  the  biologic  material  is  adsorbed.  Microarrays  have  different  applications,
such as  the  detection  of  genes  in  a  sample  (DNA  microarrays),  the  presence  of  polymorphisms,
or the  determination  of  different  gene  expressions  (mRNA  microarrays).  Microarrays  have  the
advantage  that  the  presence  and/or  expression  of  a  large  number  of  genes  can  be  analyzed
simultaneously.  Dendograms,  which  enable  the  genetic  relation  of  different  samples  to  be
observed, can  be  constructed  through  bioinformatic  analysis
Pyrosequencing  Pyrosequencing  is  a  non-ﬂuorescent  massive  sequencing  technique  that  enables  the
determination  of  nucleotide  sequences  in  a  sample.  One  of  the  advantages  of  this  technique  is
that if  a  sample  contains  a  mixture  of  bacterial  species,  they  can  each  be  identiﬁed  through
d
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ing  on  the  reported  series  and  particularly  on  the  time  of
observation.65 Prevalence  also  varies  depending  on  the  geo-
graphic  region  and  Mexico  appears  to  have  one  of  the  lowest
prevalence  rates  in  the  world,  at  only  5.0%.79 Prevalence  is
also  higher  if  it  is  evaluated  sooner  rather  than  later  after  an
infectious  outbreak.  For  example,  2  years  after  an  outbreak
of  bacterial  gastroenteritis  in  Walkerton  (Canada),  PI-IBS
prevalence  was  reported  in  30.4%  of  the  subjects  exposed
to  acute  gastroenteritis.87 Contrastingly,  in  the  following
years  the  prevalence  had  decreased  and  at  8  years  it  was
70,8815.4%. Similarly,  in  Sweden  the  initial  PI-IBS  prevalence
of  12%  was  reduced  to  9%,  5  years  later.84 In  large  reviews
it  has  been  reported  that  the  probability  (odds  ratio:  OR)
of  developing  IBS  3  months  after  an  episode  of  infectious
a
(
t
niarrhea  was  7.58-8.47  times  higher  than  in  the  control  pop-
lation,  but  at  24  to  36  months  the  OR  had  descended  to
.85-4.05.10,66
Regarding  the  causal  agent  of  PI-IBS,  the  studies  on
ncidence  and  prevalence  generally  refer  to  clinical  presen-
ations  of  IBS  after  bacterial  infections  or  the  cause  is  not
peciﬁed.  The  most  frequently  identiﬁed  bacteria  have  been
.  coli,  Campylobacter,  Shigella,  and  Salmonella.10,67,68,77,80
.  coli  was  the  cause  in  the  majority  of  the  patients  pre-
enting  with  PI-IBS  after  an  episode  of  traveler’s  diarrhea
80cquired  in  Mexico. In  a  group  of  patients  in  Houston
Texas)  16.1%  of  the  patients  with  PI-IBS  had  previously
ravelled  abroad,  whereas  only  7.5%  of  the  patients  with
on  PI-IBS  had  done  so.69 A  study  conducted  on  children
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Table  4  Incidence,  prevalence,  and  risk  factors  for  PI-IBS.
Author,
journal,
year
Country  Type  of
study
Diagnostic  criteria/Study  groups  n  Outcome  variables  Results/Conclusions  LE
Thabane  et  al.,
Aliment
Pharmacol  Ther,
200786
Canada  Systematic
review  of
prospective
controlled
studies
Manning,  Rome  I,  II,  III
IBS  in  subjects  exposed  to  acute  GE
vs
non-exposed
2,977
vs
586,523
Risk  for  PI-IBS,  risk
factors
Overall  risk:  (OR  =  5.86,  95%  CI
3.60--9.54)
3 months:  OR  =  7.58  (95%  CI
4.27--13.45)
6 months:  OR  =  5.18  (95%  CI
3.24--8.26)
12  months:  OR  =  6.37  (95%  CI
2.63--15.40)
24-36  months:  OR  =  3.85  (95%  CI
2.95--5.02);
Risk  factors  for  PI-IBS  vs  non  PI-IBS:
younger  age,  greater  anxiety  and
depression
1a
Schwille-Kiuntke
et al.,
Z Gastroenterol,
201165
Germany  Systematic
review
Subjects  exposed  to  acute  diarrhea
(epidemics,  individual  GE,  traveler’s
diarrhea)
Manning,  Rome  I,  II  IBS
6,404
(2,414;
3,764;
226)
811
Incidence,
prevalence  of
PI-IBS  at  12
months
Incidence,
post-epidemics:  7-32%;
post-individual  GE:  4-36%;
post-traveler’s  diarrhea:  4-14%;
prevalence:  7-32%
1a
Dai et  al.,
Hepatogastro-
enterology,
201266
China  Systematic
review  of
case-control
studies
Rome,  Manning  IBS
in  subjects  exposed  to  bacterial  GE
vs
non-exposed
2,721
vs
586,297
Incidence  of
PI-IBS,
risk  factors
Global:  OR  =  6.03  (95%  CI  3.58-10.13);
3 months:  OR  =  8.47  (95%  CI
4.85-14.76);
6 months:  OR  =  4.58  (95%  CI
2.94-7.14);
12  months:  OR  =  6.19  (95%  CI
2.82-13.58);
24-36  months:  OR  =  4.05  (95%  CI
3.13-5.24);  risk  factors:  female  sex,
younger  age,  severity  of  initial  insult,
enteritis  duration,  adverse
psychological  factors
3a
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Table  4  (Continued)
Author,
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Haagsma  et  al.,
Epidemiol
Infect,
201067
Hollan-d  Case-control
outcome
Rome,  Manning
IBS
in subjects  exposed  to  bacteria
vs
Campylobacter
vs
Salmonella
vs
Shigella
vs
controls
318
vs
108
vs
266
vs
322
vs
585,178
Incidence  of  PI-
IBS  at  1  year  post
GE,
AR  at  10-12
months
Incidence:  4-17%;
AR:  8.8%  (90%CI  7.2-10.4)
2b-c
Okhuysen et  al.,
Am  J
Gastroenterol,
200480
USA  Cohort
study
Rome  II
IBS,
traveler’s  diarrhea  from
enteropathogenic  and
enterotoxigenic
E.  coli
in Mexico
169  Incidence  PI-IBS  at
6 months
10%  2b
Moss-Morris et  al.,
Psychosom  Med,
200681
New
Zealand
Cohort
study
Rome  I,  II
IBS
in subjects  exposed  to  GE  from
Campylobacter
vs
infectious  mononucleosis
592
vs
243
Risk  for  PI-IBS
after  3  and  6
months
Risk  for  PI-IBS:
Campylobacter  >  Mononucleosis,
3 months:  OR  =  3.45  (95%  CI  1.75-667)
6 months:  OR  =  2.22  (95%  CI
1.11-6.67)
2b
Törnblom et  al.,
Clin
Gastroenterol
Hepatol,
200784
Sweden  Cohort
study
Rome  II  IBS  in  subjects  exposed  to
bacterial,  viral,  and  parasitic  GE
333  Prevalence  of
PI-IBS,  risk  factors
Prevalence  of  GI  symptoms,
3 months:  12%;
5  years:  9%  (68%  IBS);
risk  factors:  female  sex,  OR  =  2.65
(95%  CI  1.28-5.50);  antibiotic  use,
OR  =  2.37  (95%  CI  1.07-5.25)
2b
Marshall et  al.,
Clin
Gastroenterol
Hepatol,
200785
Canada  Cohort
study
Rome  I  IBS  in  subjects  exposed  to  GE
due to  Norovirus
135  Incidence  PI-IBS
after  3  months,
risk  factors
Incidence  in  exposed  subjects:  23.6%
vs non-exposed:  3.4%  (OR  6.9,  95%  CI
1.0--48.7,  p  =  0.014);
Risk  factor:  Vomiting  during  the  GE,
OR =  10.5  (95%  CI  1.3-85.5,  p  =  0.028)
2b
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Thabane  et  al.,
Am  J
Gastroenterol,
201071
Canada  Cohort
study
Rome  I  IBS  in  children  exposed  to
E.  coli  0157:H7,  Campylobacter  spp
467  Incidence  of  PI-IBS  Exposed  subjects:  10.5  vs
non-exposed:  2.5%,  OR  =  4.6  (95%  CI
1.6-13.3)
2b
Pitzurra et  al.,
J  Travel  Med,
201172
Switzerland  Cohort
study
Rome  III  IBS  2,476  Incidence  of  PI-IBS
in Europeans
traveling  to
destinations  with
limited  resources
IBS:  1.0%  (95%  CI  0.6-1.4)
PI-IBS:  2.8%  (95%  CI  1.7-3.9)
Unselected  IBS:  0.9%  (95%  CI  0.5-1.4);
Risk  factors  6  months  after  travel:
traveler’s  diarrhea  OR  =  3.61  (95%  CI
1.74--7.51);  adverse  life  events  1
year  prior  to  travel,  OR  =  2.58  (95%  CI
1.09-6.07);  diarrhea  4  months  before
travel  OR  =  2.5  (95%  CI  1.19--5.24)
2b
Thabane et  al.,
Am  J
Gastroenterol,
200910
Canada  Cohort
study
Nonspeciﬁed  PI-IBS  criteria  in
subjects  exposed  to  GE  from  E.  coli
0157:H7,  C.  jejuni  and  others
vs
non-exposed
1,368
vs
701
To  determine  and
validate  PI-IBS
predictive  factors
Predictors:  female  sex,  age  <  60,
longer  duration  of  diarrhea,  more
frequent  bowel  movements,
abdominal  colic,  bloody  stools,
weight  loss,  fever,  psychological
alterations  (anxiety  and  depression),
OR  =  1.05  (95%  CI  1.03-1.06,  p  <
0.0001);  these  factors  derive  from  a
numerical  scale  that  determines  low
moderate  to  high  risk  for  PI-IBS
1b
Schwille-Kiuntke
et al.,
Neurogastroenterol
Motil,
201182
Germany  Cohort
study
Rome  III  IBS
in GE  from  Salmonella
vs
Campylobacter
223
vs
249
Prevalence  of
PI-IBS,  moderate
to  severe  cases
Prevalence,  S.  enteritidis:  8.1%  vs  C.
jejuni: 12.8%;  severe  PI-IBS,
Salmonella  >  Campylobacter:
X2 =  3.984,  p  =  0.047;
risk  factors  for  IBS,  Salmonella  >
Campylobacter:  female  sex,  younger
age
2b
Villani et  al.,
Gastro-
enterology,
201076
Canada  Case-control
study  within
a  cohort
study
Rome  I  IBS  in  subjects  exposed  to
GE
vs
Exposed  subjects  without  IBS
228
vs
581
To  establish
genetic  variants
associated  with
PI-IBS
susceptibility
CDH1,  tight  junction  protein
promoters  (rs16260,  -C160A,
p =  0.0352);  IL6,  cytokine  (rs1800795,
-G174C,  p  =  0.0420);
TLR9,  innate  immune  receptor
(rs352139,  P545P,  p  =  0.0059)  and
(rs5743836,  -T1237C;  p  =  0  .0250)
2a
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Table  4  (Continued)
Author,
journal,
year
Country  Type  of
study
Diagnostic  criteria/Study  groups n  Outcome  variables  Results/Conclusions  LE
Ji  et  al.,
J  Gastroen-terol
Hepatol,
200567
South  Korea Case-control
study  within
a  cohort
study
Rome  I,  II  IBS  in  subjects  exposed  to
Shigella
vs
non-exposed
101
vs
102
Incidence  of  PI-IBS
after  12  months,
risk  factors
Incidence  in  exposed  subjects:
14.85%  vs  non-exposed:  5.88,  OR  =  2.9
(95%  CI  1.1-7.9);
Independent  risk  factor:  diarrhea
2b
Marshall et  al.,
Gut,
201070
Canada  Case-control
study  with  a
cohort  study
Rome  I  IBS  in  subjects  exposed  to  GE
due to
E.  coli  0157:H7  and  C.  jejuni
vs
non-exposed
subjects
742
vs
424
Prevalence  of
PI-IBS,
risk  factors
Prevalence,
2-3  years:  28.3%  vs  8  years:  15.4%;
risk  in  exposed  subjects  vs
non-exposed  OR  =  3.12  (95%  CI
1.99-5.04);
independent  risk  factors  at  8  years:
female  sex,  younger  age,  previous
anxiety/depression,  fever,  weight
loss during  the  acute  infection
2b
Kim et  al.,
Korean  J
Gastroenterol,
200677
South  Korea  Case-control
study  within
a  cohort
study
Rome  II  IBS  in  subjects  exposed  to
Shigella  spp
vs
non-exposed
95
vs
105
PI-IBS  at  3  years  Incidence,
1  year:  13.8%  vs  1.1%  OR  =  11.9  (95%
CI 1.49-95.58);
3 years:  14.9%  vs  4.5%  OR  =  3.93  (95%
CI 1.20-12.86);
recovery  from  PI-IBS  at  3  years:  25%
2b
Morgan et  al.,
Gastroen-terol
Res  Pract,
201273
Nicara-gua  Case-control
study  within
a  cohort
study
Rome  II  IBS  163
vs
194
Prevalence  of  IBS
in  accordance  with
parasite  burden
With  parasitosis:  16.6%  vs  controls:
15.4%,  (p  =  NS);
IBS-D:  25%,  IBS-C:  32%,  IBS-M:  43%
2b
Zanini et  al.,
Am  J
Gastroenterol,
201275
Italy  Case-control
study  within
a  cohort
study
Rome  III  IBS,
in subjects  exposed  to  norovirus
vs
non-exposed
186
vs
198
Incidence  of  PI-IBS
after  1  year
Exposed  subjects:  21.5%  vs
non-exposed:  1.5%,  OR  =  11.40  (95%
CI 3.44-37.82),  p  <  0.0001;
IBS-C:  10%,  IBS-D:  17.5%,  IBS-M:  40%,
IBS-U:  32.5%
2b
Soyturk et  al.,
Am  J
Gastroenterol,
200783
Turkey Case-control
study  within
a  cohort
study
Rome  II  IBS
in subjects  exposed  to  GE  from
Trichinella  britovi
vs
non-exposed
72
vs
27
Incidence  of  PI-IBS
at 2  months,
persistence  and
symptoms  at  4,  6,
and  12  months
Incidence  at  2  months  in  exposed
subjects:  13.9%  vs  non-exposed:  0;
persistence,
4 months:  13.9%;  6  months:  13.9%;  12
months:  7%
2b
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Table  4  (Continued)
Author,
journal,
year
Country  Type  of
study
Diagnostic  criteria/Study  groups  n  Outcome  variables  Results/Conclusions  LE
DuPont  et  al.,
Am  J  Trop  Med
Hyg,
201069
USA  Case-control  Rome  II  IBS
PI,  non  PI
(after  acute  symptom  presentation)a
221  Prevalence  of
PI-IBS  and  non
PI-IBS,  history  of
traveler’s  diarrhea
in  IBS
Prevalence,
PI-IBS:  11.4%  vs  non  PI-IBS:  24.9%
traveler’s  diarrhea,
PI-IBS:  14.0%  vs  non  PI-IBS:  4.5,
(p =  0.006)
3b
Porter et  al.,
Dig  Dis  Sci,
201178
USA  Case-control  FGID
ICD-9  564.1
in  soldiers  deployed  in  Afghanistan
vs
deployed  soldiers  without  FGID
129
vs
396
Prevalence  of
diarrhea,  to
determine
whether  diarrhea,
vomiting,  and
war-related
stressors  were  risk
factors  for  PI-  IBS
Prevalence  of  IBS:  17%;
risk  factors,
diarrhea:  OR  =  5.27  (95%  CI
2.28-12.21,  p  <  0.001);
vomiting:  OR  =  7.00  (95%  CI
2.70-18.14,  p  <  0.001)
stress:  OR  =  2.30  (1.06-4.96,  p  <  0.05)
3b
Wensaas et  al.,
Gut,
201274
Norway  Case-control  Rome  III  IBS  in  subjects  exposed  to
giardiasis
vs
non-exposed
817
vs
1,128
Prevalence  of
PI-IBS  vs  non  PI-IBS
after  3  years
PI-IBS:  46.1%  vs  non  PI-IBS:  14%
RR =  3.4  (95%  CI  2.9-3.8)
3b
Rodríguez-Fandin˜o
et al.,
Neurogas-
troenterol  Motil,
201379
Mexico  Case-control
study  within
an  experi-
mental
study
Rome  II
IBS
Spiller  PI-IBS  questionnaire
20  Prevalence  of
PI-IBS
5.0%  3b
The studies are organized from higher to lower level of evidence and then in the progressive order of the year of publication.
AR: attributable risk; C: constipation; CDH1: cadherin 1; D: diarrhea; FGID: functional gastrointestinal disorder; GE: gastroenteritis; IBS: irritable bowel syndrome; LE: level of evidence;
M: mixed; 95% CI: 95% conﬁdence interval; N: number; NS: not signiﬁcant; OR: odds ratio; PBMC: peripheral blood mononuclear cells; PI: post-infectious; RR: relative risk; spp: species;
TLR9: Toll-like receptor 9; U: unclassiﬁable.
a The acute clinical presentation considered to be GE for determining PI-IBS: fever, vomiting, abdominal pain, dysentery; urgency.
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reported  PI-IBS  in  10.5%  after  Campylobacter  infection,
compared  with  IBS  in  2.5%  of  the  children  that  were  not
exposed.71 On  the  other  hand,  bacterial  gastroenteritis
due  to  Campylobacter  is  followed  by  IBS  more  frequently
than  by  infectious  diseases  that  do  not  affect  the  digestive
tract,  such  as  infectious  mononucleosis,  for  example.81 With
respect  to  gastroenteritis  of  viral  etiology,  Norovirus  has
been  described  as  causing  PI-IBS;  the  results  of  the  2  pub-
lished  studies  on  this75,85 coincide,  reporting  that  21.5  and
23.6%  of  the  patients  had  PI-IBS,  whereas  only  1.5  and  4.4%
of  the  controls  had  IBS.  In  relation  to  the  role  of  intestinal
parasites,  the  results  are  less  conclusive.  A  Central  Ameri-
can  study  found  no  differences  in  IBS  prevalence  according
to  the  Rome  II  criteria  in  individuals  with  a  history  of  par-
asitosis  vs  subjects  with  no  such  history  (16.6%  vs  15.4%).73
On  the  other  hand,  after  a  giardiasis  outbreak  that  infected
a  large  number  of  Norwegians,  the  prevalence  of  IBS  accord-
ing  to  the  Rome  III  criteria  was  noticeably  higher  than  in  the
control  population  (46  vs  14%).74 Likewise,  in  an  outbreak
of  Trichinella  britovi  in  Turkey  that  resulted  in  72  cases  of
infection,  10  developed  IBS  (13.9%).83
In  reference  to  the  risk  factors  for  developing  PI-IBS,
the  female  sex,  the  severity  of  gastroenteritis,  and  the
presence  of  anxiety  and  depression  have  been  described.10
Villani  et  al.  analyzed  the  subjects  that  developed  PI-IBS
2  to  3  years  after  the  Walkerton  epidemic,  and  found  that
genetic  variations  associated  with  the  expression  of  the  Toll-
like  receptor  (TLR)-9  related  to  innate  immunity,  interleukin
(IL)-6  associated  with  immune  activation,  and  cadherin-1
(CDH1)  involved  in  tight  epithelial  junctions,  were  indepen-
dent  risk  factors  for  PI-IBS. 76
The  above  allows  us  to  conclude  that  the  incidence  and
prevalence  of  PI-IBS  are  variable  and  even  though  the  bac-
terial  etiology  has  been  studied  the  most,  it  appears  that
viruses  such  as  the  Norovirus  and  parasites  such  as  Giardia
may  also  be  related  to  PI-IBS.  In  addition,  risk  factors  such
as  the  female  sex,  severity  of  gastroenteritis,  and  previous
anxiety  and  depression,  as  well  as  genetic  factors  associated
with  immunity,  have  been  determined.
3.4.  4.  Low-grade  intestinal  inﬂammation  related
to post-infectious  and  non-post-infectious  irritable
bowel syndrome
•  There  is  evidence  that  suggests  the  presence  of  low-grade
intestinal  inﬂammation  in  a  subgroup  of  IBS  patients,
which  involves  an  increase  in  intraepithelial  T  lympho-
cytes  (IEL),  mast  cells  and  enterochromafﬁn  cells  (level
3  a  evidence,  grade  B  recommendation).
• The  increase  in  IEL  and  mast  cells  appears  to  be  more
commonly  observed  in  patients  with  IBS-D,  compared
with  IBS-C  and  IBS-M;  however,  whether  there  are  differ-
ences  between  PI-IBS  and  non  PI-IBS  cannot  be  concluded
(level  3  a-b  evidence,  grade  B  recommendation).
•  There  is  insufﬁcient  evidence  to  determine  whether
there  are  differences  in  the  enterochromafﬁn  cells
between  PI-IBS  and  non  PI-IBS  (level  5  evidence,  grade
D  recommendation).
A total  of  29  articles  were  identiﬁed;  2  were  system-
atic  reviews 89,90 and  the  rest  were  original  ones.91--117
a
p
p
p and  antibiotic  therapy  115
wenty-seven  studies  were  identiﬁed  in  the  initial
earch90--115,117 and  2 89,116 were  later  selected  from
ther  sources.  All  the  studies  were  conducted  on  adult
opulation,  with  the  exception  of  one  on  pediatric  pop-
lation.  Twenty-four  studies  analyzed  the  presence  of
hronic  inﬂammatory  cells  (T  lymphocytes,  mast  cells,  and
nterochromafﬁn  cells)  in  the  mucosa  of  the  colon  and
ectum  in  IBS  patients  and  controls89,91,94--104,107--108,110--118
Table  5).
For  several  years  there  have  been  reports  on  the  increase
n  the  number  of  enterochromafﬁn  cells  in  rectal  biop-
ies  of  PI-IBS  patients.99--100,106 Spiller  et  al.  reported  an  up
o  5  times  higher  increase  in  the  number  of  enterochro-
afﬁn  cells  positive  for  synaptophysin  in  patients  with  C.
ejuni  infection.95 A  gradual  decrease  in  the  number  of  ente-
ochromafﬁn  cells  was  observed  in  these  patients  in  biopsies
aken  6  and  12  weeks  after  infection;  however,  one  year
fter  the  acute  infection  in  the  subgroup  of  patients  that
emained  symptomatic,  that  is,  those  with  PI-IBS,  the  num-
er  of  enterochromafﬁn  cells  remained  elevated,  in  a  range
imilar  to  that  observed  2  weeks  after  the  C.  jejuni  infec-
ion.  The  higher  number  of  enterochromafﬁn  cells  may  have
athophysiologic  importance  because  these  cells  are  the
ain  source  of  serotonin  (5-HT)  storage  in  the  organism
nd  there  is  evidence  of  an  increase  in  5-HT  release  in  IBS
atients.119--120 The  prokinetic  and  secretory  effect  of  5-HT
ay  be  related  to  the  diarrhea  or  liquid  stools  that  accom-
any  IBS-D.  A  recent  systematic  review89 concluded  that
espite  the  fact  that  some  researchers  have  observed  an
ncrease  in  the  number  of  enterochromafﬁn  cells  and  in  the
roduction  of  serotonin  in  the  mucosa  of  the  colon  and  rec-
um  in  IBS  patients,  compared  with  healthy  controls,  many
thers  have  not  conﬁrmed  such  ﬁndings.  The  results  show
hat  these  changes  are  not  consistent.
In  addition,  some  studies  have  demonstrated  a  rise  in  the
umber  of  IEL  in  both  IBS-D  and  PI-IBS,  mainly  after  acute
astroenteritis  due  to  C.  jejuni  or  Shigella.95,111,117 Never-
heless,  it  is  not  completely  known  if  there  is  also  an  increase
n  T  lymphocytes  in  non  PI-IBS.  In  fact,  only  7  studies  com-
are  PI-IBS  and  non  PI-IBS  with  respect  to  the  inﬂammatory
hanges  encountered  through  histology.92,94,99--100,108,110--111
unlop  et  al.  found  a  higher  number  of  enterochromafﬁn
ells  and  IEL  in  PI-IBS  than  in  non  PI-IBS  and  the  controls  in
 studies,  and  therefore  suggest  that  they  could  be  mark-
rs  for  PI-IBS.99--100 Likewise,  Lee  et  al.  observed  a  greater
umber  of  enterochromafﬁn  cells,  IEL,  and  mast  cells  in
ectal  biopsies  in  PI-IBS  patients,  compared  with  non  PI-IBS
atients  and  healthy  controls.108 An  increase  in  the  num-
er  of  mast  cells  in  non  PI-IBS  was  observed  only  in  those
atients  with  IBS-D,  not  in  patients  with  IBS-C  or  IBS-M.
he  rise  in  the  number  of  mast  cells  had  been  previously
escribed  by  Weston  et  al.  in  biopsies  of  the  terminal  ileum
n  patients  with  IBS,  compared  with  the  control  group,  but
o  differentiation  was  made  between  PI-IBS  and  non  PI-
BS.93 Other  researchers  later  conﬁrmed  the  increase  in  the
umber  of  these  cells  in  IBS,96,98,101,106 mainly  in  the  IBS-D
ubgroup,  in  the  patients  with  PI-IBS,  as  well  as  in  those
ith  non  PI-IBS.  Furthermore,  the  mast  cells95--96,98,101,106
ppear  to  be  near  the  sensory  neurons,  and  there  is  a
ositive  correlation  with  the  severity  and  frequency  of
ain  and/or  abdominal  discomfort  when  they  are  in  closer
roximity. 101
116
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Table  5  Low-grade  inﬂammation  in  PI-IBS  and  non  PI-IBS.
Author,
journal,
year
Country  Type  of  study  Diagnostic  criteria/Study
groups
n  Biopsy  site  Inﬂammatory
cells  studied
Results/Conclusions  LE
Matricon  et  al.,
Aliment
Pharmacol  Ther,
201289
France  Systematic  review
of  case-control
studies  and  RCT
Manning,  Rome  I,  Rome
II, Rome  III  IBS
vs
healthy  subjects
1,282
vs
789
Terminal
ileum,
cecum,
colon,  and
rectum
Mast  cells,
IEL,  T  lym-
phocytes,
ECC
Mast  cells,  IEL,  in  the  ileum,  cecum,  colon,
and  to  a  lesser  degree  in  the  rectal  mucosa:
IBS >  controls;
ECC:  inconsistent  results
3a
Ortíz-Lucas et  al.,
Rev  Esp  Enferm
Dig,
201090
Spain  Systematic  review
of  case-control
studies  and  a  RCT
Manning,
Rome  I,  Rome  II,  Rome  III
IBS
vs
controls  (healthy
subjects,  UC,
microscopic  colitis,  FD,
NCCP,  CD,  depression)
999
vs
706
Small
bowel,
colon
IEL,  mast
cells
IEL:  there  is  evidence  of  an  increase  in  IBS
patients  vs  controls,  even  though  results  are
contradictory;
mast  cells:  there  is  evidence  of  an  increase
in the  terminal  ileum  and  ascending  colon  in
IBS patients  vs  controls
3a
Klooker et  al.,
Gut,
201091
Holland  RCT  Rome  II  IBS
(hyper  and
normosensitive  patients)
vs
healthy  subjects
60
(30,  30)
vs
22
Descending
colon,
rectum
Mast  cells  Mast  cells  +tryptase,  IBS  <  controls,  (p  <  0.05);
mast  cells  CD117,  IBS  normosensitive
patients  <  controls  (p  =  0.001)  and  tendency  in
hypersensitive  patients  (p  =  0.06)
2b
De Silva  et  al.,
Scand  J
Gastroenterol,
201292
Sri  Lanka  Case-  Control
study  within  a
cohort
Rome  III  IBS
(PI-IBS)
vs
family  history  of  colon
cancer
49
(16)
vs
14
Ileum,
colon
Mast  cells,
eosinophils,
neutrophils
Mast  cells/median  (range),  ileum,  IBS:  14.67
(8-24) vs  controls:  5.75  (4-8),  (p  <  0.001);
cecum,  IBS:  8.71  (2-14)  vs  controls:  4.00
(2-6),  (p  <  0.001);
ascending  colon,  IBS:  5.54  (3-8)  vs  controls:
3.20 (1-5),  (p  =  0.012);
descending  colon,  IBS:  8.67  (4-20)  vs
controls:  3.50  (3-4),  (p  =  0.042);
rectum,  IBS:  10.08  (7-16)  vs  controls:  4.13
(2-7),  (p  <  0.001);
no  differences  in  eosinophils,  neutrophils;
PI-IBS  vs  non  PI-IBS  was  not  analyzed
2b
Weston et  al.,
Dig  Dis  Sci,
199393
USA  Case-control  Manning  IBS
vs
healthy  subjects
20
vs
15
Terminal
ileum
Mast  cells  Cells/HPF,  IBS:  23.3  ±  3.1  vs  controls:
6.8  ±  1.1,  (p  =  0.0001);  greater  number  in
IBS-D without  specifying  if  they  were  PI-IBS
or non  PI-IBS
3b
Gwee et  al.,
Gut,
199294
Great
Britain
Case-control  Rome  I  PI-IBS
vs
exposed  subjects
without  IBS
vs
healthy  subjects
10
vs
19
vs
18
Rectum  Mononuclear
cells
PI-IBS:  105.7  ±  23.3  vs  exposed  subjects
without  IBS:  83.2  ±  29.4  vs  controls:
79.1  ±  16.9,  (p  <  0.05)
3b
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Table  5  (Continued)
Author,
journal,
year
Country  Type  of  study  Diagnostic  criteria/Study
groups
n  Biopsy  site  Inﬂammatory
cells  studied
Results/Conclusions  LE
Spiller  et  al.,
Gut,
200095
Great
Britain
Case-control  study
within  a  cohort
Rome  I  PI-IBS  vs
GE from  Campylobacter
vs
healthy  subjects
10
vs
21
vs
12
Rectum ECC,
IEL
ECC,  PI-IBS:  12.7  ±  0.4  vs  GE:  5.7  ±  1.0*  vs
controls:  1.8  ±  0.4,  (p  <  0.001);
IEL  CD8,  PI-IBS  1.8  ±  0.3  vs  GE:  0.9  ±  0.2*  vs
controls:  0.5  ±  0.2,  (p  <  0.001);
(*12  weeks);  the  changes  can  persist  up  to  1
year
2b
Walker et  al.,
Aliment
Pharmacol  Ther,
2009109
Sweden  Case-control  study
within  a  cohort
IBS-D,  IBS-C
vs
Rome  I  FD
vs
healthy  subjects
41  vs
51
vs
48
Duodenum  Mast  cells,
eosinophils,
IEL
IEL/medians,  IBS-C:  18  vs  controls:  14,
(p =  0.005),  vs  FD:  14,  (p  =  0.003);
mast  cells/medians,  IBS-C:  255  vs  IBS-D:  233,
vs controls:  145,  (IBS-C  vs  controls  p  <  0.001,
IBS-D vs  controls  p  =  0.004);
eosinophils/medians,  FD:  31  vs  controls:  17,
IBS-C:  17.5,  IBS-D:  14,  (FD  vs  controls
p <  0.001,  vs  IBS-C  p  =  0.001  vs  IBS-D
p <  0.001);
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
2b
O’ullivan et  al.,
Neurogastro-
enterol  Motil,
200096
Ireland  Case-control  s  Rome  I  IBS
vs
healthy  controls
14
vs
7
Cecum,
ascending,
descending
colon,
rectum
Mast  cells  Cecum,  IBS:  0.91  ±  0.18  (95%  CI  0.79-1.0)  vs
controls:  0.55  ±  0.14  (95%  CI  0.40-0.69);  No
differences  in  the  ascending,  descending
colon,  or  rectum
3b
Chadwick,
Gastroentero-
logy,
2002117
New
Zealand
Case-control  Rome  I  IBS
vs
controls
77
vs
28
Colon
biopsies
To
determine
histology
3  IBS  groups  were  found,  G1:  normal
histology  and  >  IEL,  LPL-CD3,  CD25
G2: >  Neutrophils,  mast  cells
G3:  Microscopic  lymphocytic  colitis
3b
Törnblom et  al.,
Gastroenterolo-
gy,
200297
Sweden  Case-control  Rome  I  IBS
vs
degenerative  visceral
neuropathy
vs
controls  that  underwent
colonoscopy
vs
autopsies
10
vs
10
vs
20
vs
15
Intestinal
wall  biopsy
in  the
proximal
jejunum
and  colon
T-
lymphocytes
and  IEL
Greater  number  of  IEL  in  the  jejunum  of  IBS
vs controls:  13.9  ±  4.0  in  controls.  There  was
peri  and  intraganglionic  location  of  the  IEL  in
IBS;
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
Park et  al.,  J  Korean
Med
Sci,
200398
South  Korea  Case-control  Rome  II  IBS
vs
healthy  subjects
14
vs
14
Cecum,
rectum
Mast  cells  Cecum,  IBS-D:  262.7  ±  35.5/mm2 vs  controls:
165.1  ±  25.3/mm2,(p  <  0.05);
rectum,  IBS-D:  184.1  ±  27.0/mm2 vs  controls:
124.6  ±  10.7/mm2,(p  <  0.05);
increased  degranulated  mast  cells  in  the
proximity  of  the  enteric  nerves;
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
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Dunlop  et  al.,
Gastroenterology,
200399
Great
Britain
Case-control  Rome  I  PI-IBS
vs
GE  due  to
Campylobacter
vs
healthy  subjects
28
vs
28
vs
34
Rectum  ECC,  IEL,
mast  cells
ECC/HPF,  PI-IBS:  35.8  ±  1.2  vs  GE:  30.6  ±  1.9,
(p =  0.022)  vs  controls:  29.1  ±  1.8  (p  =  0.006);
IEL/HPF,  PI-IBS:  127.1  ±  8.7  vs  GE:
113.4  ±  6.2,  (p  =  0.006)  vs  controls:
97.1  ±  5.7,  (p  =  0.058);
No  differences  in  mast  cells;  ECC  were  PI-IBS
predictors
3b
Dunlop et  al.,
Am  J
Gastroenterol,
2003100
Great
Britain
Case-control  Rome  II  IBS
Spiller  PI-IBS
questionnaire
vs
Non  PI-IBS  subjects
vs
healthy  subjects
23
vs
52
vs
36
Rectum  ECC,  LPL,
IEL,  mast
cells
ECC/HPF,  PI-IBS:  39.4  ±  2.9  vs  non  PI-IBS:
31.1  ±  1.5  vs  controls:  31.8  ±  1.6,  (p  =  0.012);
LPL/HPF,  PI-IBS:  120.5  ±  6.8  vs  non  PI-IBS:
118.5  ±  4.6  vs  controls:  101.6  ±  5.9,
(p =  0.042);
IEL  surface/500  cells,  PI-IBS:  41.4  ±  4.3  vs
non PI-IBS:  32.8  ±  2.7  vs  controls:  43.1  ±  3.1,
(p  =  0.036);
mast  cells/HPF,  PI-IBS:  41.9  ±  3.0  vs  non
PI-IBS: 53.0  ±  2.4  vs  controls:  45.9  ±  2.8,
(p  =  0.017)
3b
Barbara et  al.,
Gastroenterolo-
gy,
2004101
Italy  Case-control  Rome  II  IBS
vs
healthy  subjects
44
vs
22
Proximal
descending
colon
Mast  cells,
degranu-
lated  mast
cells
Mast  cells,  IBS:  9.2  ±  2.5  vs  controls:
3.3 ±  0.8,  (p  <  0.001);
IBS  greater  number  of  degranulated  mast
cells,  increased  histamine  and  tryptase
activity;
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
Wang et  al.,
World  J
Gastroenterol,
2004106
China  Case-control  IBS-D
vs
Rome  III
non  PI-
IBS-C
vs
healthy  subjects
20
vs
18
vs
20
Duodenum,
jejunum,
terminal
ileum
ECC,  mast
cells
ECC,  IBS  =  controls;
Mast  cells/HPF  in  terminal  ileum,  IBS-C:
38.7 ±  9.4  vs  IBS-D:  35.8  ±  5.5  vs  controls:
29.8  ±  4.4,  (p  <  0.001);  no  differences  in  the
duodenum  and  jejunum
3b
Ohman et  al.,
Clin  Gastroenterol
Hepatol,
2005102
Sweden  Case-control  Rome  II  IBS
(PI-IBS)
vs
UC
vs
healthy  subjects
33  (5)
vs
23
vs
15
Ascending
colon  and
sigmoid
colon
LPL
CD4,  CD8
LPL  CD8  ascending  colon,  IBS:  16.9  ±  5.9  vs
UC in  remission:  20.4  ±  5.1  vs  active  UC:
16.4  ±  6.9  vs  controls:  10.6  ±  4.4  (IBS,  UC
remission  vs  controls,  p  =  0.01;  active  vs
controls,  p  =  0.05);
no  differences  in  the  sigmoid  or  CD4  in  the
ascending  or  sigmoid;  PI-IBS  vs  non  PI-IBS  was
not  analyzed
3b
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Tunc  et  al.,
Acta  Médica,
2005103
Turkey Case-control  Nonspeciﬁed  criteria
IBS
vs
IBD
vs
healthy  subjects
11
vs
5
vs
5
Cecum  Mast  cells IBS:  39.3  ±  11.2  vs  IBD:  22.2  ±  4.2  (p  <  0.01)
vs controls:  13.2  ±  1.9  (p  <  0.001);  PI-IBS  vs
non PI-IBS  was  not  speciﬁed
3b
Park et  al.,
Gastroenterol
Hepatol,
2006104
South  Korea Case-control  Rome  II  IBS-D
Non-PI
vs
healthy  subjects
18
vs
15
Terminal
ileum,
ascending
colon,
rectum
Mast  cells Terminal  ileum,  IBS:  49.1  ±  7.4  vs  controls:
37.9  ±  5.8,  (p  <  0.01);
Ascending  colon,  IBS:  47.7  ±  7.1  vs  controls:
37.4  ±  6.2,  (p  <  0.01);
Rectum,  IBS:  47.8  ±  7.6  vs  controls:
37.3  ±  6.0,  (p  <  0.01)
3b
Guilarte et  al.,
Gut,
2007105
Spain  Case-control  Rome  II  IBS-D
(PI-IBS)
vs
healthy  subjects
20  (6)
vs
14
Jejunum  IEL,  mast
cells
IEL  CD3+  IBS-D:  15.3  ±  5.5  (95%  CI  12.7-17.9)
vs controls:  10.3  ±  3.9  (95%  CI  8.0-12.5),
(p =  0.006);
mast  cells/HPF,  IBS-D:  34  ±  9.3  vs  controls:
15.3  ±  4.4,  (p  <  0.001),  higher  tryptase  levels;
mast cells,  PI-IBS:  32.3  ±  5.9  (95%  CI
26.0-38.5)  vs  non  PI-IBS:  34.7  ±  10.2  (95%  CI
28.8-0.6),  (p  =  NS)
3b
Piche et  al.,
Gut,
2008107
France  Case-control  Rome  II
non  PI-IBS
vs
healthy  subjects
vs
depression/
fatigue
50
vs
21
vs
11
Cecum  Cellularity,
IEL,  mast
cells
Cellularity/HPF,  IBS:  94.5  (95%  CI  48-110)  vs
controls:  68  (95%  CI  58-82),  (p  =  0.005),  vs
depression:  78  (95%  CI  87-90),  (p  =  0.05);
mast  cells,  IBS:  9.3  (95%  CI  5.6-11.7)  vs
controls:  4.0  (2.7-6.8),  (p  =  0.001)  vs
depression:  4.3  (95%  CI  2.8-7.8),  (p  =  0.005)
3b
Lee et  al.,
Gastroenterol
Hepatol,
2008108
South  Korea Case-control  Rome  III
(PI-IBS)
vs
healthy  subjects
42
(5)  vs
12
Rectum ECC,  mast
cells,  LPL
ECC/HPF,  IBS:  10.9  ±  4.5  vs  PI-IBS:  16.8  ±  0.8
vs non  PI-IBS:  10.1  ±  4.1  vs  controls:
8.0 ±  3.9,  (IBS  vs  controls  p  <  0.05,  PI-IBS  vs
controls  p  <  0.01);
mast  cells/HPF,  IBS:  8.6  ±  2.6  vs  PI-IBS:
10.6 ±  3.8  vs  non  PI-IBS:  8.3  ±  2.8  vs  controls:
6.8  ±  2.0,  (all  vs  controls  p  ≤  0.05);
LPL/HPF,  IBS:  34.0  ±  12.2  vs  PI-IBS:  43.4  ±  8.7
vs non  PI-IBS:  32.7  ±  12.2  vs  controls:
30.2  ±  12.6,  (PI-IBS  vs  controls  p  <  0.05);
mast  cells,  non  PI-IBS-D:  8.8  ±  2.2  vs
controls:  6.8  ±  2.0;  (p  <  0.05)
3b
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Cremon  et  al.,
Am  J
Gastroenterol,
2009113
Italy  Case-control  Rome  II  IBS
vs
healthy  subjects
25  vs
12
Colon  ECC
(5-HT+),
mast  cells
ECC,  greater  area  of  the  crypt  epithelium
occupied  by  these  cells  in  IBS:  0.56  ±  0.26%
vs controls:  0.37  ±  0.16%,  (p  =  0.039),  and
greater  in  IBS-D:  0.69  ±  0.24%  vs  IBS-C:
0.44 ±  0.22%,  (p  =  0.34)
Mast  cells,  greater  area  of  the  lamina  propria
occupied  by  these  cells  in  IBS:  9.8  ±  2.9%  vs
4.5 ±  2.8%,  (p  <  0.01),  with  no  differences  in
IBS-D  vs  IBS-C;
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
Bhuiyan et  al.,
Mymensingh  Med
J,
2010110
Bangla-desh  Case-control  Rome  II  PI-IBS
vs
non  PI-IBS
vs
healthy  subjects
18
vs
32
vs
10
Sigmoid
colon
IEL,
mast  cells
IEL:
IBS  >  controls  (p  <  0.001),
lymphoid  follicles:
IBS  >  controls  (p  <  0.05);
mast  cells:
IBS  >  controls  (p  <  0.05)  and  in  PI-IBS  vs  non
PI-IBS  (p  <  0.001)
3b
Kim et  al.,  Yonsei
Med  J,  2010111
South  Korea  Case-control  IBS-D
Rome  II
vs
PI-IBS
Post  Shigellosis
vs
non  PI-IBS
vs
healthy  subjects
7
vs
4
vs
7
vs
10
Descending,
sigmoid
colon,
rectum
ECC,
IEL,
LPL,
Mast  cells
IEL/HPF,
sigmoid  colon,  PI-IBS:  13.41  ±  5.57  vs  non
PI-IBS: 7.22  ±  1.20  vs  IBS:  11.49  ±  1.31  vs
controls:  5.91  ±  0.82,  (p  =  0.024);  rectum,
PI-IBS:  11.40  ±  4.17  vs  non  PI-IBS:  5.83  ±  0.73
vs IBS:  8.19  ±  0.73  vs  controls:  4.77  ±  0.85
(p =  0.033);
CD3,
descending,  PI-IBS:  30.4  ±  3.09  vs  non  PI-IBS:
25.97  ±  4.57  vs  IBS:  25.90  ±  3.77  vs  controls:
17.69  ±  5.82,  (p  =  0.024);  sigmoid  colon,
PI-IBS:  29.80  ±  7.37  vs  non  PI-IBS:
24.09  ±  3.07  vs  IBS:  25.51  ±  3.20  vs  controls:
13.82  ±  2.83,  (p  =  0.039);  rectum,  PI-IBS:
25.0 ±  2.96  vs  non  PI-IBS:  25.31  ±  3.57  vs  IBS:
20.67 ±  1.29  vs  controls:  14.89  ±  1.53,
(p =  0.013);
CD8/HPF,
descending  colon,  PI-IBS:  69.00  ±  10.87*  vs
non PI-IBS:  36.11  ±  3.91  vs  IBS:  35.00  ±  5.37
vs controls  32.56  ±  18.57,  (p  =  0.031),  (*PI-IBS
vs non  PI-IBS,  p  <  0.05);
mast  cells,  with  no  differences  except  in  the
descending  PI-IBS:  105.3  ±  13.3  vs  non  PI-IBS:
52.8  ±  13.44,  (p  <  0.05)
3b
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Goral  et  al.,
Hepatogastro-
enterology,
2010112
Turkey Case-control  Rome  III  IBS-C,  IBS-D
vs
healthy  subjects
32,  40  vs
50
Rectum Mast  cells Mast  cells  present  in  patients  with  IBS-D:
77.5%  vs  IBS-C:  59.4%  vs  controls:  56.0%
(p <  0.0001);
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
Arévalo et  al.,
Rev  Gastroenterol
Perú,
2011114
Peru Case-control  Rome  III  IBS
vs
healthy  subjects
16
vs
9
Ascending,
descending
colon
IEL,  mast
cells,
eosinophils,
ECC
LIE/100  epithelial  cells,  IBS:  9.81  vs  controls:
4.66  (p  =  0.002);
no  differences  in  mast  cells,  eosinophils,  and
ECC,  or  IBS-D  vs  IBS-C;
PI-IBS  vs  non  PI-IBS  was  not  speciﬁed
3b
Braak et  al.,
Am  J
Gastroenterol,
2012115
Holland  Case-control  Rome  II  IBS
(PI-IBS)
vs
healthy  subjects
66
(9)  vs
20
Descending,
sigmoid
colon
Mast  cells,  T
lymphocytes
Descending  colon
LT-CD3,  IBS:  493  ±  34  vs  controls:  587  ±  66,
(p =  NS);
LT-CD8,  IBS:  388  ±  28  vs  controls:  526  ±  50,
(p =  0.02);
mast  cells,  IBS:  370  ±  39  vs  controls:
186  ±  10,  (p  <  0.001)
macrophages,  IBS:  729  ±  64  vs  controls:
1,261  ±  146  (p  <  0.003);
ascending,  no  differences;
PI-IBS  vs  non  PI-IBS  was  not  analyzed,  only
acute  onset  IBS
< macrophages  vs  gradual  onset  IBS,  (p  =  0.02)
3b
Chang et  al.,
Am  J
Gastroenterol,
2012116
USA  Case-control  Rome  II
non  PI-IBS
vs
healthy  subjects
45
vs
41
Sigmoid
colon
Immune
cells
CD3,  CD4,  CD8  lymphocytes,  ECC,  EEC,  Mast
cells, IBS  =  controls,
(p =  0.059-0.892)
3b
The studies are organized from higher to lower level of evidence and then in the progressive order of the year of publication. In regard to the Systematic Reviews, the country corresponds
to that of the authors that conducted the study. In the diagnostic criteria/study groups and n columns the corresponding subgroup of those with IBS is in parentheses.
C: constipation; CD: celiac disease; D: diarrhea; ECC: enterochromafﬁn cells; FD: functional dyspepsia; GE: gastroenteritis; HPF: high power ﬁeld; IEL: intraepithelial lymphocytes; IBD:
inﬂammatory bowel disease; IBS: irritable bowel syndrome; LE: level of evidence; LPL: lamina propria lymphocytes; NCCP: noncardiac chest pain; Non PI: non-post-infectious; N: number;
PI: post-infectious; RCT: randomized controlled trial; UC: ulcerative colitis.
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In  contrast,  Braak  et  al.  reported  a  decrease  in  the  IEL,
acrophage,  and  mast  cell  count  in  the  colonic  mucosa  in
6  patients  with  IBS,  compared  with  20  healthy  controls.115
n  that  study,  the  difference  between  PI-IBS  and  non  PI-IBS
as  not  speciﬁcally  analyzed,  but  rather  the  patients  with
cute  and  gradual  IBS  onset  were  compared,  and  a  lower
umber  of  macrophages  was  observed  in  those  with  grad-
al  IBS  onset.115 It  is  likely  that  the  sudden  onset  group
orresponds  to  PI-IBS,  but  we  cannot  conclude  that.  Pre-
iously,  another  study  by  the  same  group  in  Holland  not  only
ound  a  lower  number  of  mast  cells  in  biopsies  of  the  rec-
um  and  descending  colon  in  IBS,  but  also  reduced  tryptase
elease,  compared  with  the  controls.91 Finally,  Chang  et  al.
ound  no  differences  in  the  number  of  immune  cells  in  the
olonic  mucosa  between  patients  with  non  PI-IBS  and  the
ontrols.116
The  above  suggests  that  there  is  an  increase  in  IEL,  mast
ells,  and  enterochromafﬁn  cells  in  the  intestinal  mucosa
n  a  group  of  patients  with  IBS  that  appears  to  be  more
requent  in  those  with  IBS-D.  However,  it  cannot  be  deter-
ined  whether  this  low-grade  inﬂammation  is  characteristic
f  PI-IBS  or  non  PI-IBS.
.5.  5.  Altered  bowel  function  in  irritable  bowel
yndrome related  to  post-infectious  irritable  bowel
yndrome,  SIBO  and/or  microbiota  alterations
 The  evidence  suggests  that  the  differences  in  the  compo-
sition  of  the  microbiota  in  subjects  with  IBS  are  related  to
alterations  in  the  visceral  sensitivity  and  motility  func-
tion  of  the  gastrointestinal  tract  (level  1  b  evidence,
grade  A  recommendation).
 The  presence  of  methanogenic  microbiota  is  signiﬁcantly
associated  with  constipation  predominant  IBS  (IBS-C)
(level  3a  evidence,  grade  B  recommendation).
Eight  articles  related  to  bowel  function22--23,35,60,94,121--123
ere  identiﬁed  in  the  initial  search  and  3  addi-
ional  articles104,124--125 were  identiﬁed  from  other  sources
Table  6).  The  evidence  suggests  that  the  changes  in  the
icrobiota  of  the  patients  with  IBS  have  an  inﬂuence  on
isceral  sensitivity  and  gastrointestinal  motility,  especially
t  the  antroduodenal  and  colorectal  level.22--23,35,60,94,121--126
egarding  the  sensory  distubances,  the  studies  have  shown
hat  some  patients  with  IBS  and  dysbiosis  (PI-IBS  and  IBS
ith  SIBO)  develop  rectal  hypersensitivity,  one  of  the  most
haracteristic  pathophysiologic  ﬁndings  in  IBS.94
Various  studies  have  also  described  that  patients  with  PI-
BS  have  faster  colonic  transit  time.  For  example,  Gwee
t  al.  demonstrated  that  subjects  with  a  history  of  gas-
roenteritis  and  IBS  had  faster  colonic  transit  than  a  control
roup  of  healthy  subjects  (median  colonic  transit  time  of
4.4  vs  55.2  min,  p  =  0.01).94 In  contrast,  Yu  et  al.  found  that
he  orocecal  transit  time  correlated  with  the  IBS  subtype.35
hus,  orocecal  transit  is  longer  in  patients  with  IBS-C  than
n  those  with  IBS-D  (p  =  0.0023).
Moreover,  in  patients  with  IBS  and  evidence  of  SIBO
lterations  in  the  number  and  frequency  of  phase  III  activ-
ties  of  the  migrating  motor  complex  (MMC)  have  been
escribed.22--23,121 For  example,  in  a  group  of  patients  with
BS  according  to  the  Rome  I  criteria  and  SIBO  based  on  a  pos-
tive  LBT,  Pimentel  et  al.  demonstrated  that  the  number  of
•M.  Schmulson  et  al.
vents  of  phase  III  of  the  MMC  was  lower  in  patients  with  IBS
nd  SIBO  than  in  the  healthy  controls  (0.7  vs  2.2,  p  <  0.001);
he  same  was  true  for  the  phase  III  duration  (305  vs  428  s,
 < 0.001).121
Numerous  studies  have  suggested  that  patients  with  IBS
ave  qualitative  changes  in  the  colonic  ﬂora.  For  exam-
le,  there  are  descriptions  of  patients  that  can  develop  a
roliferation  of  bacterial  species  that  produce  more  gas,
peciﬁcally  methane.  The  presence  of  methanogenic  ﬂora  in
atients  with  IBS  has  been  associated  with  a  slower  colonic
ransit  time,  rectal  hyposensitivity,  and  altered  intestinal
otility.122--125 In  a  recent  analysis  of  the  microbiota  in
atients  with  IBS  through  the  technique  of  pyrosequencing,
effery  et  al.  demonstrated  that  17  taxas  are  associated
ith  a  slow  colonic  transit  time  (including  those  of  the
ollowing  phylotypes:  Euryarchaeota, those  of  the  class:
ethanobacteria, and  those  of  the  families:  Methanobacte-
iaceae  and  Desulfohalobiaceae).60 Likewise,  the  presence
f  Proteobacteria  is  described  as  being  associated  with  an
ncrease  in  the  pain  threshold  during  rectal  distension,  eval-
ated  using  a barostat.  In  addition,  the  ﬁrst  evidence  in  IBS
f  the  detection  of  different  levels  of  acetic  acid,  propionic
cid,  and  total  fatty  acids  has  been  reported.  The  highest
evels  are  associated  with  poor  outcome  IBS.
In  summary,  the  evidence  suggests  that  changes  in  the
omposition  of  the  microbiota  or  its  instability  (dysbiosis)
ave  an  inﬂuence  on  the  gastrointestinal  physiology,  produc-
ng  abnormalities  in  visceral  sensitivity  and  gastrointestinal
otility.  However,  further  studies  are  required  in  order  to
etermine  the  effect  of  the  microbiota  on  those  sensory
nd  motor  alterations.  On  the  other  hand,  it  is  not  known
hether  these  disturbances  contribute  to  symptom  gen-
ration  or  whether  they  are  the  consequence  of  primary
otility  disorders.  Finally,  it  should  be  stressed  that  there
re  other  factors  that  have  an  inﬂuence  on  the  microbiota  of
atients  with  IBS,  such  as  the  type  of  diet  (i.e.  FODMAPs:  fer-
entable  oligosaccharides,  disaccharides,  monosaccharides
nd  polyols)  and  the  use  of  antibiotics.
.6.  6.  Antimicrobials  in  the  treatment  of  irritable
owel syndrome
 In  patients  with  non-constipation  IBS,  rifaximin  at  doses
of  400  mg  TID  for  10  days  or  550  mg  TID  for  14  days,  is
superior  to  placebo  in  the  adequate  response  of  global
IBS  symptoms  and  in  abdominal  bloating.  It  also  improves
pain  and  abdominal  discomfort,  as  well  as  the  consis-
tency  of  loose/liquid  stools  during  treatment  and  for  up
to  10  weeks  post-treatment  (level  1  b  evidence,  grade  A
recommendation).
 Rifaximin  at  a  dose  of  400  mg  TID  for  7  days  may  neutral-
ize  the  LBT  in  approximately  half  the  patients  with  IBS,
which  is  associated  with  reduced  IBS  symptom  severity
(level  4  evidence,  grade  C  recommendation).
 The  frequency  of  adverse  events  is  similar  between  rifax-
imin  and  placebo,  and  the  most  frequent  are:  headache,
upper  respiratory  tract  infections,  nausea,  nasopharyn-
gitis,  diarrhea,  and  abdominal  pain  (level  1  b  evidence,
grade  A  recommendation).
 In  the  patients  that  require  retreatment  with  rifaximin,
effectiveness  appears  to  be  similar  to  that  of  the  ﬁrst
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Table  6  Altered  bowel  physiology  in  relation  to  PI-IBS,  SIBO,  and  microbiota  alterations.
Author,
journal,
year
Country  Type  of
study
Diagnostic  criteria/Study
groups
n  Outcome  variables Results/Conclusions LE
Kunkel  et  al.,
Dig  Dis  Sci,
2011124
USA  Systematic
review
+
Meta-
analysis  of
case-control
studies
IBS
unreported  criteria
CH4+
vs
CH4-
319
vs
958
Relation  of  CH4+  to
constipation
CH4,  constipation:  OR  =  3.51  (95%  CI
2.00-6.16);  IBS-C:  OR  =  3.60  (95%  CI
1.61-8.06)
3a
Gwee et  al.,
Gut,
199994
Great
Britain
Case-control  Rome  I  PI-IBS
subjects  exposed  to  GE
vs
Non-IBS  exposed  to  GE
vs
healthy  subjects
94
vs
22
vs
72
Symptom  questionnaire,
HADS,
Bx  of  the  rectum,
rectal  distension  with
syringe,  colonic  transit  with
radio-opaque  markers
Colonic  transit,  PI-IBS  <  healthy
subjects;  rectal  hypersensitivity  and
hyperactivity,  PI-IBS  >  healthy
subjects
3b
Pimentel et  al.,
Dig  Dis  Sci,
2002121
USA  Case-control  Rome  I  IBS
+SIBO
vs
healthy  subjects
68
vs
30
LBT,
AD  manometry
Phase  III  of  MMC,  number  of  events,
IBS:  0.7  vs  controls:  2.2,
(p  <  0.000001);  duration,  IBS:  305  s  vs
controls:  428  seconds,  (p  <  0.001)
3b
Pimentel et  al.,
Dig  Dis  Sci,
2003122
USA  Case-control  Subjects  given  breath  test
IBD
vs
Rome  I
IBS
(IBS-C,  IBS-D)
78
vs
296
(120,
111)
LBT,
symptom  questionnaire
Methane+:  >  symptom  severity  in
IBS-C  (p  <  0.05)  and  <  IBS-D  (p  >
0.001).
Methane+,  IBS-C:  52.3%  vs  IBS-D:  0,
(p <  0.001)
3b
Posserud et  al.,
Gut,
200722
Sweden  Case-control  Rome  II  IBS
vs
Controls
162
vs
26
LBT,  duodenal  aspirate
culture,
duodenal  Bx,  AD  manometry
Dysmotility,  IBS  with  SIBO:  86%  vs
without:  39%  (p  =  0.02);  N  of  phases
III  of  the  MMC,  SIBO:  Median  0.6
(Range  0-1.8)  vs  1.2  (0--4)  /  3  hours,
(p =  0.08)
3b
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Table  6  (Continued)
Author,
journal,
year
Country  Type  of
study
Diagnostic  criteria/Study
groups
n  Outcome  variables  Results/Conclusions  LE
Grover  et  al.,
Neurogas-
troenterol
and  Motility,
200823
USA  Case-control  Rome  II  IBS
vs
healthy  subjects
158
vs
34
SBT  and  CH4,
barostat,
colonic  manometry  (MI),
IBS-QOL  and  IBS-SS
IBS  patients  had  an  increase  in  MI
after  rectal  distension  vs  HC.  There
was  no  difference  between  IBS  with
SIBO  and  IBS  without  SIBO.  The
CH4-producers  had  a  greater
sensitivity  threshold  for  urgency  to
defecate  (28  vs  18  mmHg,  p  <  0.05)
and  higher  MI  (461  vs  301.45,
p <  0.05)  vs  IBS  without  SIBO.
3b
Park et  al.,
Gut  and
Liver,
2009126
South  Korea  Case-control  Rome  II  IBS
vs
healthy  subjects
38
vs
12
LBT,
intestinal  permeability  with
PEG
Intestinal  permeability,  IBS:
0.82  ±  0.09  vs  controls:  0.41  ±  0.05,
(p <  0.05);  IBS  with  SIBO:  0.90  ±  0.13
vs  without:  0.80  ±  0.11,  (p  =  NS)
3b
Jeffery et  al.,
Gut.,
201160
Ireland  and
Sweden
Case-control  Rome  II  IBS
vs
healthy  subjects
37
vs
20
Microbiota  through
pyrosequencing  in  fecal
matter,  colonic  transit  with
radio-opaque  markers,
rectal  barostat
Microbiota  and  ST,  phylotype:
Euryarchaeota,  class:
Methanobacteria  and  families:
Methanobacteriaceae  and
Desulfohalobiaceae
Firmicutes:Bacteroides  ratio  to  pain
and rectal  distension,  IBS  >  controls
3b
Furnari et  al.,
J  Gastrointes
Liv  Dis,
2012125
Italy  Case-control  Symptom-based  IBS  patients
given  GBT
vs
healthy  subjects
629
vs
40
GBT  (H2  and  CH4),
symptom  diary
CH4,  IBS-C:  32.3%  vs  controls:  30%
(p  =  NS);  constipation:  27.4%  vs
diarrhea:  17.1%,  (p  <  0.001);  CH4
production  (ppm),  FC  vs  controls,
(p  =  0.04),  vs  diarrhea  (p  =  0.002)
3b
Yu et  al.,
Gut,
201035
Canada  Case  series  Rome  II  IBS  40  LBT,
orocecal  transit  with  Tc99
scintigraphy
Orocecal  transit,  IBS:  7167  min
(range10-220  min);  IBS-C  vs  IBS-D:  >
2.2  times,  (p  =  0.0023)
4
The studies are organized from higher to lower level of evidence and then in the progressive order of the year of publication.
AD: antroduodenal; C: constipation; CH4: methane; CI: conﬁdence interval; D: diarrhea; FC: functional constipation; GBT: glucose breath test; HADS: hospital anxiety and depression
scale; HC: healthy controls; H2: exhaled hydrogen; IBD: inﬂammatory bowel disease; IBS: irritable bowel syndrome; IBS-QOL: quality of life questionnaire for irritable bowel syndrome;
IBS-SS: irritable bowel syndrome severity scale; LBT: lactulose breath test; MMC: migrating motor complex; MI: motility index; NS: not signiﬁcant NT: normal transit; OR: odds ratio; PEG:
polyethylene glycol; ppm: parts per million; SBT: sucrose breath test; SIBO: small intestinal bacterial overgrowth; ST: slow transit.
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iMicrobiota,  gastrointestinal  infections,  low-grade  inﬂammat
treatment;  however,  further  studies  are  required  in  order
to  determine  the  effectiveness  of  retreatment  and  the
appropriate  interval  for  carrying  it  out  (level  4  evidence,
grade  C  recommendation).
•  Studies  are  required  for  evaluating  the  long-term  safety
and  effectiveness  of  rifaximin  in  IBS  (level  5  evidence,
grade  D  recommendation).
Twenty  articles  that  analyzed  antibiotic  therapy  in
IBS  were  identiﬁed,  5  reviews 15,127--130 and  15  original
articles,18,33,131--143 all  studies  on  adults,  except  one  con-
ducted  on  the  pediatric  population.135 An  additional  original
article  that  had  been  published  in  December  2013  was  added
37 (Table  7).
Basically  2  antibiotics  have  been  studied  in  IBS:  rifaximin
and  neomycin.  Rifaximin  is  a  semi-synthetic  antibiotic,  an
analog  of  rifamycin,  designed  to  have  little  gastrointestinal
absorption.  It  inhibits  the  bacterial  synthesis  of  RNA  by  bind-
ing  to  the  RNA  polymerase    subunit  that  is  dependent  on
bacterial  DNA.144 Its  absorption  is  less  than  0.4%,  making  it
an  almost  completely  luminal-acting  antibiotic,  and  most  of
it  is  excreted  in  the  fecal  matter,  unchanged.  It  has  a  broad
spectrum  of  activity  against  Gram-positive,  Gram-negative,
aerobic,  and  anaerobic  enteropathogens145--146 with  a  low
probability  of  bacterial  resistance.147--148 In  vitro  it  induces
CYP3A4,  but  its  interaction  with  other  medications  is  almost
null.129
In  the  selected  reviews,15,127--131 a  short  cycle  of
non-absorbable  antibiotics,  like  rifaximin,  has  been  recom-
mended  for  improving  global  IBS  symptoms.131 The  authors
of  a  systematic  review  with  only  3  original  articles  on  rifax-
imin  treatment  of  IBS  with  or  without  SIBO  concluded  that
rifaximin  at  a  dose  of  400  mg  BID  for  7  to  10  days,  improves
IBS  symptoms,  regardless  of  whether  SIBO  is  present  or
not.129 In  2  later  systematic  reviews  with  meta-analyses  pub-
lished  2  years  apart,  the  second  one  with  10  times  more
patients  treated  with  rifaximin  vs  placebo,  it  was  concluded,
and  with  a  good  level  of  evidence,  that  the  antibiotic  at
doses  of  400  to  550  mg,  2  to  3  times/day,  was  twice  as
effective  as  the  placebo  at  improving  IBS  symptoms.15,127
Additionally,  rifaximin  showed  a  therapeutic  gain  of  9.8  over
the  placebo  and  a  number  needed  to  treat  (NNT)  of  10.2  for
global  IBS  improvement  and  very  similar  values  for  abdomi-
nal  bloating  improvement.15,127 In  another  systematic  review
on  the  treatment  of  abdominal  bloating,  it  was  concluded
that  rifaximin  was  superior  to  placebo  in  the  proportion  of
patients  with  IBS-Non  C  that  reported  subjective  improve-
ment  in  abdominal  bloating.129
The  original  articles  analyzed  rifaximin  and  neomycin,
as  well  as  a  few  other  antibiotics.  However,  the  studies
have  different  designs  and  include  retrospective  studies,
case  series,  and  randomized  controlled  trials  with  placebo
or  other  antibiotics  and  different  doses.  For  example,
rifaximin  has  been  studied  from  doses  of  200  mg  QID,137
400  mg  BID  or  TID  for  7  to  14  days,  to  550  mg  TID  for  14
days.15 Likewise,  the  outcome  variables  analyzed  were  very
different  in  each  of  the  studies,  from  global  IBS  improve-
ment  to  improvement  of  secondary  symptoms  such  as  pain
and/or  abdominal  bloating,  to  the  frequency  and  consis-
tency  of  bowel  movements.131,132,134 The  effect  of  rifaximin
on  GBT136,137 or  LBT33 has  been  evaluated  as  well.  These
differences  in  the  studies  make  it  difﬁcult  to  arrive  at  a
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onclusion.  Nevertheless,  the  best  evidence  comes  from  the
ecent  Target  1  and  Target  2  studies  by  Pimentel  et  al.,  with
ore  than  1,200  patients  between  the  2  investigations.134
hey  show  that  rifaximin  at  a  dose  of  550  mg  TID  for  14  days
n  patients  with  IBS-Non  C  by  Rome  II  criteria  resulted  in
 greater  proportion  of  patients  with  adequate  relief  from
BS  symptoms,  abdominal  bloating,  daily  symptom  intensity,
bdominal  pain,  and  stool  consistency.134 In  the  follow-up
t  10  weeks  post-treatment,  adequate  relief  deﬁned  as  the
ubjective  report  of  symptom  improvement  in  at  least  one
f  every  2  weeks,  rifaximin  remained  signiﬁcantly  superior
o  placebo.  It  is  worth  noting  that  it  had  previously  been
eported  that  at  lower  doses,  such  as  400  mg  BID  or  TID  for
0  days,  rifaximin  was  also  superior  to  placebo  in  the  per-
entage  of  patients  that  reported  overall  improvement  of
BS.131--132 Regarding  secondary  effects,  in  the  Target  1  and  2
tudies,  which  are  the  largest,  frequency  was  similar  to  the
lacebo  (1.6%  with  rifaximin  and  2.4%  with  placebo)  and  the
ain  effects  in  order  of  frequency  were  headache,  followed
y  respiratory  tract  infections,  abdominal  pain,  nausea,  and
iarrhea.134
Furthermore,  rifaximin  can  neutralize  LBT  in  52%  of  the
atients  with  Rome  II-IBS  and  in  this  subgroup  symptom
everity  improved,  but  the  corresponding  study  was  not
ontrolled,33 and  neither  were  those  that  evaluated  the
ffect  on  GBT.136,137 Regarding  the  effect  on  children,  a  dose
f  550  mg  TID  for  10  days  showed  no  differences  from  the
lacebo  or  in  LBT  normalization,  which  was  achieved  in
nly  20%.135 This  suggests  that  children  most  likely  require
igher  doses  or  a  different  type  of  antibiotic,  probably  due
o  a  more  resistant  microbiota.  In  reference  to  rifaximin
etreatment,  only  one  retrospective  study  analyzed  this
odality;  patients  treated  up  to  5  times  had  a  mean  inter-
al  of  symptom  recurrence  of  4  months.143 Effectiveness  was
5%,  similar  to  that  of  the  ﬁrst  treatment.  However,  well-
esigned  studies  are  required  in  order  to  determine  how
ften  rifaximin  can  be  repeated.143 Finally,  no  studies  have
valuated  the  long-term  effects  of  rifaximin  in  IBS.
Regarding  neomycin,  it  is  a  systemic  aminoglycoside  that
as  been  evaluated  in  2  original  studies  on  IBS,18,138 both
f  which  are  randomized  and  controlled  with  placebo.  At
 dose  of  500  mg  BID  for  7  to  10  days  in  patients  with
BS  in  general  in  one  study,  and  IBS-C  by  Rome  I crite-
ia  in  the  other,  neomycin  was  superior  to  the  placebo  in
he  percentage  of  patients,  mainly  those  with  a  positive
BT,  that  reported  improvement  in  a  composite  score  of
ymptoms  including  abdominal  pain,  diarrhea,  bloating,  and
owel  habit.18 Neomycin  normalized  LBT  in  only  20%  of  the
atients,  but  in  the  methane-positive  patients,  the  percent-
ge  that  reported  improvement  in  regard  to  constipation
as  9  times  higher  with  neomycin  than  with  placebo.138
espite  this,  neomycin  is  not  an  ideal  drug  for  IBS  because
f  its  characteristics  in  relation  to  systemic  absorption  and
ts  safety  spectrum.
With  regard  to  other  antibiotics,  a  retrospective  study
as  conducted  that  compared  rifaximin  with  neomycin,
oxycycline,  and  amoxicillin-clavulanic  acid  that  were  used
n  the  management  of  the  treatment  and  retreatment  of
IBO  in  patients  with  IBS;141 however,  these  agents  were
ot  as  effective  as  rifaximin.  Erythromycin  has  also  been
tudied,  evaluating  the  number  of  days  until  IBS  symptom
ecurrence  after  LBT  neutralization,  but  it  was  much  less
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Table  7  Antibiotic  therapy  in  IBS.
Author,
journal,
year
Country  Type  of
study
Diagnostic
criteria/Study
groups
Treatment  dose  N  Outcome  variables  Results/Conclusions  LE
Rezaie  et  al.,
Arch  Med  Sci,
2010127
Iran  Systematic
review  +
meta-
analysis
Any  criteria  IBS  Rifa  400  mg
vs
Pb
BID-TID  x  7-10
days
80
vs
74
Efﬁcacy  of  antibiotics  in
IBS
Rifa  superior  to  Pb,
clinical  response  in  IBS:  RR  =  2.04,
(95%  CI  1.23-3.40,  p  =  0.0061);
symptom  response:  RR  =  2.06,  (95%  CI
1.3-3.27,  p  =  0.002)
1a
Menees et  al.,
Am  J
Gastroente-rol,
201215
USA  Systematic
review  +
Meta-
analysis
Any  criteria  IBS  Rifa  400-550  mg
vs
Pb
BID-TID  x  10-14
days
895
vs
908
Efﬁcacy  and  tolerability
of rifa  in  IBS
Global  relief,  rifa  superior  to  Pb:
OR  =  1.57,  (95%  CI:  1.22-2.01);
therapeutic  gain:  9.8,  NNT:  10.2;
Abdominal  bloating:  OR  =  1.55,  (95%
CI: 1.23-1.96);  therapeutic  gain:  9.9,
NNT:  10.1;  adverse  events:  rifa  =  Pb
1a
Schmulson, Chang,
Aliment
Pharmacol
Ther,
2011129
Mexico,
USA
Systematic
review
Any  criteria,
abdominal
bloating
Rifa  400-550  mg
vs
Pb
BID-TID  x  7-14
days
704
vs
708
Efﬁcacy  in  abdominal
bloating
Rifa  is  effective  in  abdominal  bloating
improvement  in  non-constipation  IBS
1a
Fumi, Trexler,  Ann
Pharmacol,
2008128
USA  Systematic
review
Any  criteria
IBS
with  or  without
SIBO
Rifa  400  mg
vs
Pb
BID-TID  x  7-10
days
113
vs
30
Efﬁcacy  of  rifa  in  IBS
symptoms
A  third  of  the  IBS  patients  show
clinical  improvement  with  rifa,
particularly  if  they  have  SIBO
2a
Kwon et  al.,
Korean  J
Gastroente-rol,
2011130
South
Korea
Review  Rome  I  or  II  IBS  Rifa,
neo,
other  antibiotics,
controls
127,
44,
61,
63
Evidence-based
consensus  and  the  Delphi
Method
A short  cycle  of  non-absorbable
antibiotics  (rifa  or  neo)  can  improve
the overall  symptoms  of  IBS,
particularly  in  IBS-D
3
Scarpellini et  al.,
Aliment
Pharmacol  Ther,
2007133
Italy  RCT  SIBO
+
Rome  II  IBS
Rifa  400  mg  TID
vs
Rifa
400-800-400  mg  x
7 days
33
vs
30
GBT  GBT  normalization,
rifa-1200:  58%  vs  rifa-1600:  80%,
(p <  0.05)
1b
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Table  7  (Continued)
Author,
journal,
year
Country  Type  of
study
Diagnostic
criteria/Study
groups
Treatment  dose N  Outcome  variables  Results/Conclusions  LE
Pimentel  et  al.,
New  Eng  J  Med,
2011134
USA  RCT  Rome  II
IBS  Non-C
Rifa  550  mg
vs
Pb,
TID  x  14  days,
follow-up  for  x  10
weeks;
2  studies
Target  1
309
vs
314
Target  2
315
vs
320
%  of  adequate  relief  of
overall  symptoms  in  2/4
weeks  (weeks  3-6),  daily
symptom  intensity
Adequate  improvement,
rifa:  40.7  vs  Pb:  31.7,  (p  <  0.001);
abdominal  bloating,
rifa:  40.2  vs  Pb:  30.3  (p  <  0.001);
daily  intensity  (overall  symptoms,
abdominal  pain,  bloating,  stool
consistency),
rifa  >  Pb  (all  signiﬁcant)
1b
Pimentel et  al.,
Am  J
Gastroente-rol,
200318
USA  RCT  Rome  I  IBS Neo  500  mg
vs
Pb
BID  x  7  days
55
vs
56
Improvement  >50%  in
composite  score  (pain,
diarrhea,  constipation),
bowel  habit
normalization
Improvement  >  50%,
neo:  35.0  ±  5.0%  vs  Pb:  11.4  ±  9.3%,
(p <  0.05);
bowel  habit,  neo:  40.1  ±  5.3%  vs  Pb:
15.1 ±  3.6%,  (p  <  0.001);
IBS  +  LBT,  improvement  >50%,  neo:
35.4  ±  5.6%  vs  Pb:  3.7  ±  10.6%,
(p <  0.01)
2b
Pimentel et  al.,
Dig  Dis  Sci,
2006138
USA  RCT  Rome  I  IBS-C  Neo  500  mg
vs
Pb
BID  x  10  days
20
vs
19
%  of  global
improvement,
constipation  and/or
abdominal  pain,
constipation
improvement  in  CH4+
Global  improvement,
neo:  36.7  ±  7.9  vs  Pb:  5.0  ±  3.2%,
(p  <  0.001);
constipation,  neo:  32.6  ±  9.9%  vs
18.7  ±  7.2%,  (p  =  0.26);
CH4+,  neo:  44.0  ±  12.3%  vs  Pb:
5.0 ±  5.1%,  (p  =  0.05)
2b
Pimentel
et al.,
Ann  Intern  Med,
2006131
USA  RCT  Rome  I  IBS Rifa  400  mg
vs
Pb
TID  x10  days  &
follow-up  x  10
weeks
43
vs
44
Global  improvement,
secondary  symptoms
(pain,  bloating,
diarrhea,  constipation)
Global  improvement,
rifa:  36.40  ±  31.46%  vs  Pb:
21.00  ±  22.08%  (p  <  0.020);
only  bloating  improved  (p  <  0.010)
2b
Sharara
et al.,
Am  J
Gastroen-terol,
2006132
Lebanon  RCT  Bloating  and
ﬂatulence-IBS
Rome  II  subgroup
Rifa  400  mg
vs
Pb,
BID x  10  days  and
follow-up  x  10
days
37
vs
30
Subjective  global  relief
(pain,  bloating,  number
and  frequency  of  bowel
movements,  incomplete
evacuation)
At  10  days,  patients  improved  with
rifa:  40.5%  vs  Pb:  18.2%  (p  =  0.04);
ten-day  follow-up,  patients  improved
with  rifa:  27.0  vs  Pb:  9.1%,  (p  =  0.05)
2b
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Table  7  (Continued)
Author,
journal,
year
Country  Type  of
study
Diagnostic
criteria/Study
groups
Treatment  dose  N  Outcome  variables  Results/Conclusions  LE
Collins,  Lin,
J  Pediatr
Gastroen-terol
Nutr,  2011135
USA  RCT  Children  with  CAP
Rome  II-IBS
subgroup
Rifa  550  mg
vs
Pb
TID  x  10  days  &
follow-up  x  2
weeks
26
vs
15
Symptoms
(bloating,  gas,
incomplete  evacuation,
pain,  diarrhea,
constipation,  urgency,
mucus,  straining,
incontinence)
VAS:  0-10,  LBT
Symptoms,
rifa  =  Pb;
LBT  normalization,
rifa:  80%  vs  Pb:  86%
2b
Cuoco et  al.,
Minerva
Gastroente-rol
Dietol,
2006136
Italy  Case  series  IBS  symptoms
and
+GBT
Rifa  400  mg
TID  x14  days
23  GBT  and
post-treatment
symptoms
vs  basal
GBT,
normalized  in  82.6%  (p  <  0.01);  IBS
symptoms  disappeared,  in  42%,
(p <  0.05);  diarrhea,  bloating,  and
abdominal  pain  improvement,
(all:  p  <  0.05)
4
Majewski et  al.,
Adv  Med  Sci,
2007137
USA  Case  series  Rome  II  IBS
and
+GBT
Rifa  200  mg
QID  x  30  days
8  Overall
improvement(bowel
movement  frequency,
pain,  bloating,  gas)  and
GBT
Rifa  normalized  symptoms  in  7
patients  and  GBT  in  6  patients
4
Morken et  al.,
Scand  J
Gastroente-rol,
2009139
Sweden  Case  series  Rome  II  IBS-D
post-Giardia
eradication
Rifa  200  mg  TID  x  8
days  +  metro
400  mg  BID  x  10
days
vs
live  fecal  ﬂora
instilled  in  the
duodenum
18
vs
10
Symptom  score  (nausea,
pain,  bloating,  diarrhea,
constipation,  anorexia)
and  H+  through  LBT
Symptoms,  rifa+metro:  tended  to
decrease  at  4  weeks  (p  =  0.07);
fecal  ﬂora:  diminished  at  7  weeks
(p =  0.0009)  but  were  the  same  12
months  later;  H+,  rifa:  decreased  at
90-120  min,  fecal  ﬂora:  no  changes,
there  was  no  group  comparison
4
Weinstock et  al,
Dig  Dis  Sci,
2008140
USA  Case  series  IBS  symptoms
and
+LBT
and
restless  legs
syndrome
Rifa  400  mg,
TID  x  10  days.
Then  tegaserod
3  mg  +  zinc  200  mg
+ probiotic,  QD  x
30  days
13  N  with  global  symptom
and  %  of  individual
symptom  improvement
Improvement  above  80%:  in  10
patients;
complete  resolution:  in  5;  abdominal
pain:  74%;  diarrhea:  73%;  bloating:
70%;  postprandial  fullness:  65%;
constipation:  64%;  ﬂatulence:  47%
4
M
icrobiota,
 gastrointestinal
 infections,
 low
-grade
 inﬂ
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m
ation,
 and
 antibiotic
 therapy
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Author,
journal,
year
Country  Type  of
study
Diagnostic
criteria/Study
groups
Treatment  dose N  Outcome  variables  Results/Conclusions  LE
Yang  et  al,
Dig  Dis  Sci,
2008141
USA  Case  series Rome  I IBS
and
+LBT
Rifa  400  mg  TID,
neo,
others:
doxycycline,
augmentin
84,
24,
61
%  of  responders
(improvement  >  50%),
LBT
Rifa:  68%  vs  neo:  38%  vs  others:  44%,
(both:  p  <  0.01);
normal  LBT  was  a  response  predictor:
81%  of  responders  (p  <  0.001)
4
Peralta et  al.,
World  J
Gastroenterol,
200933
Italy  Case  series Rome  II  IBS
+LBT
Rifa  400  mg
TID  x  7  days
54  LBT  normalization  (N),
symptom  severity  (Likert
0-4)
LBT  normalization:  52,
symptom  severity,
-LBT:  2.3  ±  0.6  vs  0.9  ±  0.8
(p  =  0.003);
+LBT:  no  changes
4
Pimentel et  al,
Gastroen-terol
Hepatol
(NY),
2009142
USA  Case  series IBS  Nonspeciﬁed
criteria
and
SIBO
(LBT)
+  Symptom
resolution
Eryth  50  mg,
teg  2-6  mg,
eryth  followed  by
teg,
no  treatment
followed  by  eryth
or teg,  QD
42,
16,
20,
6
Time  until  recurrence
(days  free  from
symptoms)
Eryth:  138.5  ±  132.2  vs  teg:
241.6  ±  162.2,  (p  =  0.004)  vs  no
treatment  (p  =  0.08);  no  treatment
followed  by  eryth:  41.0  ±  44.8  vs
followed  by  teg:  195.6  ±  153.3,
(p =  0.06);  eryth  followed  by  teg:
extended  105.8  ±  73.3  to
199.7  ±  162.9  (p  =  0.04)
4
Pimentel et  al.,
Dig  Dis  Sci,
2011143
USA  Case  series Nonspeciﬁed
criteria
IBS  Non-C
Rifa
nonspeciﬁed  dose
148  N  with  re-treatments,
% of  re-treatment
response
1  re-treatment:  71;  2:  48;  3:  22;  4:  7;
5: 4;
improvement  with  ﬁrst  treatment:
75%;  subsequent  improvement:  75%;
recurrence  minimum:  4  months
4
Meyrat et  al.,
Aliment
Pharmacol  Ther,
201237
Switzerland  Case  series Rome  III Rifa  200  mg
QID  x  14  days
106  Symptom  severity
(Likert:  0-10)  weeks  4
and  14  post-treatment
and
LBT  at  4  weeks  (N  =  64)
Symptoms  at  4  weeks,
bloating:  5.5  ±  2.6  vs  3.6  ±  2.7,
(p  <  0.001);
ﬂatulence:  5.0  ±  2.7  vs  4.0  ±  2.7,
(p =  0.015);
diarrhea:  2.9  ±  2.4  vs  2.0  ±  2.4,
(p  =  0.005);
abdominal  pain:  4.8  ±  2.7  vs
3.3  ±  2.5,  (p  <  0.001);
general  well  being:  3.9  ±  2.4  vs
2.7  ±  2.3,  (p  <  0.001);
LBT  normalization:  86%
4
The studies are organized from higher to lower level of evidence and then in the progressive order of the year of publication.
BID: twice a day; CAP: chronic abdominal pain; CH4: methane D: diarrhea; Eryth: erythromycin; GBT: glucose breath test; H+: exhaled hydrogen; IBS: irritable bowel syndrome; LBT:
lactulose breath test; LE: level of evidence; N: number; Neo: neomycin; 95% CI: 95% conﬁdence interval; NNT: number needed to treat; OR: odds ratio; Pb: placebo; QD:  once a day; QID:
4 times a day; RCT: randomized controlled trial; Rifa: rifaximin; RR: relative risk; SIBO: small intestinal bacterial overgrowth; Teg: tegaserod; TID: 3 times a day; VAS: visual analog scale
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ffective  than  tegaserod.142 And  ﬁnally,  rifaximin  together
ith  metronidazole  has  been  evaluated  in  post-giardiasis-
BS,  but  no  conclusion  can  be  reached  in  relation  to  this
tudy.139
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